Novel crispr-associated (cas) protein

ABSTRACT

A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Division of U.S. application Ser. No. 17/097,880,filed 13 Nov. 2020, which is a Continuation of U.S. application Ser. No.15/937,840 filed 27 Mar. 2018 (now U.S. Pat. No. 10,876,101), whichclaims benefit of, and priority to, U.S. Provisional Application Nos.62/477,494, filed 28 Mar. 2017, and 62/629,641, filed 12 Feb. 2018, thecontents of each are incorporated herein by reference in theirentireties.

TECHNICAL FIELD

The present invention relates to Clustered Regularly Interspaced ShortPalindromic Repeats (CRISPR) systems. In particular, the inventionrelates to a new CRISPR-associated (Cas) protein, termed “CasM,” and theuses of CasM for site-specific nucleic acid engineering.

BACKGROUND OF THE INVENTION

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) andCRISPR-associated (Cas) proteins are found in prokaryotic immunesystems. These systems provide resistance against exogenous geneticelements, such as viruses and plasmids, by targeting their nucleic acidsfor degradation, in a sequence-specific manner.

There are several different CRISPR-Cas systems and the nomenclature andclassification of these have changed as the systems have beencharacterized. In particular, CRISPR-Cas systems have now beenreclassified into two classes, containing several types and subtypes(Makarova et al., Nature Reviews Microbiology (2015) 13:1-15; Shmakov etal., Nature Reviews Microbiology (2017) 15; 169-182). Thisclassification is based upon identifying all cas genes in a CRISPR-Caslocus and then determining the signature genes in each CRISPR-Cas locus,thereby determining whether the CRISPR-Cas systems should be placed ineither Class 1 or Class 2 based upon the genes encoding the effectormodule, i.e., the proteins involved in the interference stage.

There remains a need to discover and characterize new CRISPR-associated(Cas) proteins, and their potential use for site-specific nucleic acidengineering.

SUMMARY

The present invention is based on the discovery of a new Cas protein,termed “CasM” herein. This protein shares no homology to any known Casprotein or to any known protein family.

Accordingly, in one aspect, the invention is directed to an isolatedCasM protein capable of producing a single-strand break at an RNA targetsite when guided to the RNA target site by a cognate nucleic acid guide.In certain embodiments, the cognate nucleic acid guide comprises RNA,such, as crRNA, in additional embodiments, the CasM protein comprises anamino acid sequence selected from the group consisting of the amino acidsequence of SEQ ID NOS:37-44 or 45; an ortholog of the amino acidsequence of SEQ ID NOS:37-44 or 45, i.e., a CasM sequence from a speciesother than the species producing the reference sequence; and a variantof the amino acid sequence of SEQ ID NOS:37-44 or 45, e.g., an activehomology of the reference amino acid sequence.

In further embodiments, the invention is directed to a complexcomprising a CasM protein, and a cognate nucleic acid guide. In certainembodiments, the cognate nucleic acid guide in the complex comprises arepeat sequence and a spacer sequence, wherein the repeat sequence andthe spacer sequence do not naturally occur together. In certainembodiments, the cognate nucleic acid guide comprises a modified baseanalog.

In additional embodiments, the cognate nucleic acid guide comprises RNA,such as, but not limited to, crRNA. In some embodiments, the cognatenucleic acid guide, such as crRNA, comprises a spacer sequence that iscomplementary to a DNA or RNA target sequence that occurs in aprokaryotic or eukaryotic cell.

In further embodiments, the crRNA/CasM protein complex is capable ofbinding to a first RNA target sequence complementary to the crRNA spacersequence, wherein binding of the crRNA/CasM protein complex results inthe cleavage of a first RNA target. In additional embodiments, afiercleavage of the first RNA target sequence by the crRNA/CasM proteincomplex, the complex is capable of non-specific endonuclease activitytoward any single-stranded RNA in a sequence independent manner.

In further embodiments, the complex modifies the transcription ortranslation of a target locus in cell.

In additional embodiments, the invention is directed to an isolatedpolynucleotide encoding a CasM protein, wherein the CasM protein iscapable of producing a single-strand break at an RNA target site whenguided to the RNA target site by a cognate nucleic acid guide. Incertain embodiments, the cognate nucleic acid guide comprises RNA, suchas crRNA. In additional embodiments, the CasM protein encoded by thepolynucleotide comprises an amino acid sequence selected from the groupconsisting of the amino acid sequence of SEQ ID NOS:37-44 or 45; an orholog of the amino acid sequence of SEQ ID NOS 37-44 or 45, i.e., a CasMsequence from a species other than the species producing the referencesequence; and a variant of the amino acid sequence of SEQ ID NOS:37-44or 45, e.g., an active homolog of the reference amino acid sequence.

In further embodiments, the invention is directed to a modifiedpolynucleotide encoding a CasM protein, wherein the CasM protein iscapable of producing a single-strand break at an RNA target site whenguided to the RNA target site by a cognate nucleic acid guide, whereinthe polynucleotide is modified relative to its native sequence, such asmodified for expression in a selected host cell. In additionalembodiments, the CasM protein encoded by the polynucleotide comprises anamino acid sequence selected from the group consisting of the amino acidsequence of SEQ ID NOS:37-44 or 45; an ortholog of the amino acidsequence of SEQ ID NOS:37-44 or 45, i.e., a CasM sequence from a speciesother than the species producing the reference sequence; and a variantof the amino acid sequence of SEQ ID NOS:37-44 or 45, e.g., an activehomolog of the reference amino acid sequence.

In certain embodiments, the polynucieotide is modified for expression ina bacterial cell, such as for expression in an Escherichia coli cell. Incertain embodiments, the polynueleotide comprises the sequence of SEQ IDNOS:2-8 or 9.

In other embodiments, the polynucleotide is modified for expression in aeukaryotic cell, e.g., a mammalian cell, such as a human cell. Incertain embodiments, the polynucleotide comprises the sequence of SEQ IDNOS:10-17 or 18.

In additional embodiments, the polynucleotide is modified for expressionin a plant cell, such as for expression in a Zea mays (corn) cell. Incertain embodiments the polynucleotide comprises the sequence of SEQ IDNOS:19-26 or 27.

In further embodiments, the invention is directed to a recombinantvector comprising a polynucleotide or modified polynucleotide asdescribed herein, and at least one control element operably linked tothe polyaucleotide, whereby a CasM coding sequence in the polynucleotideis capable of being transcribed and translated in a host cell. Incertain embodiments, at least one of the control elements isheterologous to the coding system.

In additional embodiments, the CasM protein encoded by thepolynucleotide comprises an amino acid sequence selected from the groupconsisting of the amino acid sequence of SEQ ID NOS:37-44 or 45; anortholog of the amino acid sequence of SEQ ID NOS:37-44 or 45; and avariant of the amino acid, sequence of SEQ ID NOS:37-44 or 45.

In further embodiments, the invention is directed to a host celltransformed with a recombinant vector described herein. In certainembodiments, the host cell is a prokaryotic or eukaryotic cell.

In additional embodiments, the invention is directed to a method ofproducing a CasM protein comprising providing a population of host cellstransformed with a recombinant vector as described herein; and culturingthe population of cells under conditions whereby the CasM proteinencoded hy the polynucleotide present in the recombinant vector isexpressed.

In further embodiments, the invention is directed to a eukaryotic hostcell comprising a CasM protein of a complex comprising the CasM protein,as described herein.

In additional embodiments, the invention is directed to a method ofdirecting a CasM protein to a selected nucleic acid target sequence,comprising contacting the selected nucleic acid target sequence with acognate nucleic acid guide/CasM complex that targets said selectednucleic acid target sequence, whereby the CasM protein is delivered tothe nucleic acid target sequence. In certain embodiments, the nucleicacid target sequence comprises RNA, such as mRNA. In furtherembodiments, the method comprises producing one or more single- ordouble-strand breaks in the target sequence.

In additional embodiments, the method is performed in a cell, such as aprokaryotic or eukaryotic cell. In certain embodiments, the cellconstitutively expresses the CasM protein. In other embodiments, e.g.,when the cell does not constitutively express the CasM protein, thecognate nucleic acid guide is complexed to the CasM protein prior todelivery to the nucleic acid target sequence. In other embodiments, thecell constitutively expresses the CasM protein and the cognate nucleicacid guide. In additional embodiments, the complex modifies thetranscription or translation of a selected nucleic acid sequence in ahost cell, such as a sequence.

In further embodiments of the methods, the CasM protein comprises anamino acid sequence selected from the group consisting of the amino acidsequence of SEQ ID NOS:37-44 or 45; an ortholog of the amino acidsequence of SEQ ID NOS:37-44 or 45; and a variant of the amino acidsequence of SEQ ID NOS:37-44 or 45.

In other embodiments of the methods, a donor polynucleotide is deliveredto the region of the selected nucleic acid target sequence.

In additional embodiments, the CasM protein is capable of processing theCRISPR repeat-spacer array into individual repeat-spacer elements. TheCasM protein cleaves the array within the 5′ region of each repeatsequence, giving rise to a processed crRNA comprising, in a 5′ to 3′direction, a repeat sequence and a spacer element.

In some embodiments the repeat sequence comprises a secondary structurethat is recognized by the CasM protein. The secondary structure of therepeat may comprise a stem, a stem-loop duplex, a pseudoknot, or atripartite duplex. CasM protein homologs may only recognize the repeatsequence or secondary structure of their cognate repeat elements,Alternatively, CasM protein homologs may recognize the repeat sequenceor secondary structure of non-cognate repeat elements.

In some embodiments the crRNA/CasM complex is capable ofsequence-specific single-stranded RNA activity. Recognition and cleavageof an initial ssRNA complementary to the crRNA target sequence activatesthe CasM protein to carry out endonuclease activity toward anysingle-stranded RNA in a sequence-independent manner. Thesequence-specific recognition of RNA of the crRNA/CasM complexfacilitates the target knockdown of gene transcripts perturbingtranslation of a specific protein. The non-specific endonucleaseactivity of an activated crRNA/CasM complex in a cellular environmentcan result in cell death due to depletion of RNA encoding for essentialgene transcripts. The specific RNA targeting and collateral endonucleaseactivity of an activated crRNA/CasM complex enables thesequence-specific selection of cells expressing a RNA transcript.

In a further aspect, the present invention relates to a method ofscreening and killing cells that have not been modified by a DNAtargeting nuclease (e.g., a Type II Cas9 nuclease). This methodcomprises contacting a crRNA/Cas9 complex to a locus of interest in apopulation of cells. Contacting the NATNA/Cas9 complex results in DNAcleavage and subsequent repair of the break by the endogenous cellularrepair machine and the introduction of insertion and deletions(“indels”) at the break site. The targeting of the NATNA/Cas9 to atargeted locus that encodes an RNA traitscript results in indels in anRNA transcript sequence. This modified RNA transcript sequence isdifferent compared to a transcript from an unmodified cell (a wild-typecell). A cognate nucleic acid guide/CasM complex can then be targeted tothe unmodified transcript, wherein recognition of the unmodifiedtranscript by the complex results in activation of the sequenceindependent, single-stranded RNA targeting activity of the CasM proteinand subsequent cell death. Alternatively, this method can be adapted toscreen for the incorporation of a donor-polynucleotide into NATNA/Cas9break site.

These aspects and other embodiments of the present invention willreadily occur to those of ordinary skill in the art in view of thedisclosure herein.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

SEQUENCE LISTING

The sequences referred to herein are listed in the Sequence Listingsubmitted as an ASCII text file entitled“LOCN-006_C02US_SeqList.ST25.txt”-306 KB and was created on Nov. 13,2020. The Sequence Listing entitled “LOCN-006_C02US_SeqList_ST25.txt” isincorporated herein by reference in its entirety.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts a representative CasM operon from Eubacterinm siraeum(NCBI Accession No. NZ_DS4995.551.1).

FIG. 2 shows a structure of a CasM repeat sequence (SEQ ID NO:51).

FIG. 3 shows the results of the in vitro CRISPR array cleavage assaydescribed in the Examples.

FIG. 4 shows a depiction of a synthetic CasM CRISPR array.

FIG. 5 shows a representation of the results of the in vitro CRISPRarray cleavage assay results shown in FIG. 3 and described in theExamples.

FIG. 6 shows the results of the CasM ssRNA cleavage assay described inthe Examples.

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that the terminology used herein is for thepurpose of describing particular embodiments only, and is not intendedto be limiting. As used in this specification and the appended claims,the singular forms “a,” “an” and “the” include plural referents unlessthe context clearly dictates otherwise. Thus, for example, reference toa “guide/Cas complex” includes one or more such complexes, reference to“a polynucleotide” includes one or more polynucleotides, etc.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention pertains. Although other methods andmaterials similar, or equivalent, to those described herein can be usedin the practice of the present invention, preferred materials andmethods are described herein.

In view of the teachings of the present specification, one of ordinaryskill in the art can apply conventional techniques of immunology,biochemistry, chemistry, molecular biology, microbiology, cell biology,genomics, and recombinant polynucleotides, as taught, for example, bythe following standard texts: Antibodies: A Laboratory Manual, Secondedition, E. A. Greenfield, 2014, Cold Spring Harbor Laboratory Press,ISBN 978-1-936113-81-1; Culture of Animal Cells: A Manual of BasicTechnique and Specialized Applications, 6th Edition, R. I. Freshney,2010, Wiley-Blackwell, ISBN 978-0-470-52812-9; Transgenic AnimalTechnology, Third Edition: A Laboratory Handbook, 2014, C. A. Pinkert,Elsevier, ISBN 978-0124104907; The Laboratory Mouse, Second Edition,2012, H. Hedrich, Academic Press, ISBN 978-0123820082 Manipulating theMouse Embryo: A Laboratory Manual, 2013, R. Behringer, at al., ColdSpring Harbor Laboratory Press, ISBN 978-1936113019; PCR 2: A PracticalApproach, 1995, M. J. McPherson, at al., IRL Press, ISBN 978-0199634248;Methods in Molecular Biology (Series), J. M. Walker, ISSN 1064-3745,Humana Press; RNA: A Laboratory Manual, 2010, D. C. Rio, et al., ColdSpring Harbor Laboratory Press, ISBN 978-0879698911; Methods inEnzymology (Series), Academic Press; Molecular Cloning: A LaboratoryManual (Fourth Edition), 2012, M. R. Green, et al., Cold Spring HarborLaboratory Press, ISBN 978-1605500560; Bioconjugate Techniques, ThirdEdition, 2013, G. T. Hemians Academic Press, ISBN 978-0123822390;Methods in Plant Biochemistry and Molecular Biology, 1997, W. V. Dashek,CRC Press, ISBN 978-0849394805; Plant Cell Culture Protocols (Methods inMolecular Biology), 2012, V. M. Loyola-Vargas, et al., Humana Press,ISBN 978-1617798177; Plant Transformation Technologies, 2011, C. N.Stewart, et al., Wiley-Blackwell, ISBN 978-0813821955; RecombinantProteins from Plants (Methods in Biotechnology), 2010, C. Cunningham, etal., Humana Press, ISBN 978-1617370212; Plant Genomics: Methods andProtocols (Methods in Molecular Biology), 2009, D. J. Somers, et al.,Humana Press, ISBN 978-1588299970; Plant Biotechnology: Methods inTissue Culture and Gene Transfer, 2008, R. Keshavachandran, et al.,Orient Blackswan, ISBN 978-8173716164.

As used herein, “a CasM protein” refers to a CRISPR protein capable oftargeting RNA and causing single-strand RNA breaks when guided to atarget site by a crRNA, without the necessity of association with atracrRNA. CasM proteins typically include two or more higher eukaryoticand prokaryotic nucleotide-binding (HEPN) domains found in proteinfamily PF05168 in the C-terminal region of the CasM sequence. CasMproteins show synteny with one or more WYL domain-containing proteinsand sometimes with RtcB (RNA 3′-terminal phosphate cyclase, group B)domain-containing proteins. Based on the foregoing characteristics, CasMmay be classified as a Class 2 Type VI CRISPR-Cas system because it is asingle effector protein containing two HEPN domains used for targetedssRNA interference. However, CasM has a very low degree of sequencesimilarity to other Type VI subtypes. Exemplary CasM proteins, are shownin SEQ ID NOS:37-45, and are encoded by polynucleotides shown in SEQ IDNOS:28-36, respectively. These proteins display approximately 13.59% to99.82% sequence identity to each other and show less than 8% sequenceidentity with other known CRISPR-Cas proteins. As used herein, the term“CasM protein” refers to a CasM protein derived from any species,subspecies, or strain of bacteria that encodes the CasM protein, as wellas an ortholog of the CasM protein, i.e., a CasM protein from a speciesother than the species producing the reference CasM protein. Forexample, CasM orthologs of Eubacterium siraeum CasM, shown in Table 1,display approximately 13.59% to 99.82% sequence identity to each other.Thus, CasM orthologs are identified based on the Casivi characteristicsdetailed herein. Reference to a CasM protein also encompasses a variantof the reference CasM protein, e.g., an active homolog of the referenceamino acid sequence. Thus, CasM proteins include, but are not limitedto, those proteins depicted in SEQ ID NOS:37-45, orthologs thereof, orvariants thereof. Non-limiting examples of such proteins include CasMproteins from Eubacterium siraeum; Ruminaeoccus sp., such as fromRuminococcus bicirculans; Ruminococcus flavefaciens, such as, but notlimited to, FD-1 and strain XPD3002; Ruminococcus albus such as, but notlimited to, strain KH2T6; Ruminococcus sp. isolates, such as but notlimited to, isolates 2789STDY5834971, 27895TDY5608892 and2789STDY5834894.

By “dCasM protein” is meant a deactivated CasM protein lacking activity,such as catalytic and/or binding activity, also termed “dead CasM.” Suchmolecules lack all or a portion of biological activity, such as nucleaseand/or binding activity, and are therefore unable to bind and/or cleavea target nucleic acid of interest, respectively. In some embodiments,these deactivated CasM proteins can be used to regulate genes in anucleic acid-guided manner. This is accomplished by introducingmutations that inactivate CasM nuclease function and typically involvesmutating catalytic residues of the gene encoding CasM. dCasM can be usedalone or in fusions to synthetically repress (CRISPR interference orCRISPRi) or activate (CRISPR activation or CRISPRa) gene expression.CRISPRi can work independently of host cellular machineries. In someembodiments a dCasM protein and a customized nucleic acid-targetingnucleic acid, i.e., a cognate nucleic acid guide designed with acomplementary region to any gene of interest, are used to direct dCasMto a chosen genomic location. In other embodiments, dCasM can be fusedto a transcription factor, such as a repressor, and the fuseddCasM-transcription factor can then work in concert with cellularmachineries. CRISPRa is carried out by dCasM-transcription factor(activator) fusions.

A “nucleic acid-targeting nucleic acid” (NATNA), as used herein, refersto one or more polynucleotides that guide a protein, such as a CasMprotein, to preferentially target a nucleic acid target sequence presentin a polynucleotide (relative to a polynucleotide that does not comprisethe nucleic acid target sequence). Such NATNAs are also known herein as“cognate nucleic acid guides,” or “cognate guides.” NATNAs can compriseribonucleotide bases (e.g., RNA); deoxyribonucleotide bases (e.g., DNA),combinations of ribonucleotide bases and deoxyribonucleotide bases(e.g., RNA/DNA), nucleotides, nucleotide analogs, modified nucleotides,and the like, as well as synthetic, naturally occurring, andnon-naturally occurring modified backbone residues or linkages. Thus, aNATNA as used herein site-specifically guides a CasM, or a deactivatedCasM, to a target nucleic acid. Many such NATNAs are known, such as butnot limited to sgRNA (including miniature and truncated single-guideRNAs), crRNA, dual-guide RNA, including but not limited to,crRNA/tracrRNA molecules, as described herein, and the like, the use ofwhich depends on the particular Cas protein. For a non-limitingdescription of exemplary NATNAs, see, e.g., PCT Publication No. WO2014/150624 to May et al., published Sep. 29, 2014; PCT Publication No.WO 2015/200555 to May et al., published Mar. 10, 2016; PCT PublicationNo. WO 2016/201155 to Donohoue et al., published Dec. 15, 2016; PCTPublication No. WO 2017/027423 to Donohoue et al., published Feb. 16,2017; and PCT Publication No. WO 2016/123230 to May et al., publishedAug. 4, 2016; each of which is incorporated herein by reference in itsentirety.

With reference to a NATNA or a cognate nucleic acid guide, a “spacer,”“spacer sequence,” or “spacer element,” as used herein, refers to thepolynucleotide sequence that can specifically hybridize to a targetnucleic acid sequence. The spacer element interacts with the targetnucleic acid sequence through hydrogen bonding between complementarybase pairs (i.e., paired bases). A spacer element binds to a selectednucleic acid target sequence. Accordingly, the spacer element is thenucleic acid target-binding sequence. The spacer element determines thelocation of a Cas protein's site-specific binding and nucleolyticcleavage. Spacer elements range from approximately 17 to approximately84 nucleotides in length and have an average length of 36 nucleotides(see, e.g., Marraffini, et al., “CRISPR interference: RNA-directedadaptive immunity in bacteria and archaea” Nature reviews Genetics(2010) 11:1814190). Variability of the functional length for a spacerelement is known in the art (e.g., U.S. Patent Publication 2014/0315985to May et al., published Oct. 23, 2014, incorprated herein by referencein its entirety). The terms “nucleic acid target binding sequence” and“spacer sequence” are used interchangeably herein.

The term “sgRNA” typically refers to a single-guide RNA (i.e., a single,contiguous polynucleotide sequence) that essentially comprises a or RNAconnected at its 3′ end to the 5′ end of a tracrRNA through a “loop”sequence (see, e.g., U.S. Published Patent Application No. 2014/0068797to Doudna et al., published 6 Mar. 2014, incorporated herein byreference in its entirety), sgRNA interacts with a cognate Cas proteinessentially as described for tracrRNA/crRNA polynucleotides. Similar tocrRNA, sgRNA, has a spacer, a region of complementarity to a potentialDNA or RNA target sequence, adjacent a second region that formsbase-pair hydrogen bonds that form a secondary structure, typically astem structure. The term includes truncated single-guide RNAs(tru-sgRNAs) of approximately 17-18 nucleotides (nt) (see, e.g., et al.,Nat Biotechnot. (2014) 32; 279-284). The term also encompassesfunctional miniature sgRNAs with expendable features removed, but thatretain an essential and conserved module termed the “nexus” located inthe portion of sgRNA that corresponds to tracrRNA (not crRNA). See,e.g., U.S. Patent Publication 2014/0315985 to May et al., published Oct.23, 2014, incorporated herein by reference in its entirety; Briner etal., “Guide RNA Functional Modules Direct Cas9 Activity andOrthogonality,” Molecular Cell (2014) 56:333-339.

As used herein, “dual-guide RNA” refers to a two-component RNA systemfor a polynucleotide component capable of associating with a cognate Casprotein. A representative CRISPR Class 2 Type II CRISPR-Cas-associateddual-guide RNA includes a Cas-crRNA and Cas-tracrRNA, paired by hydrogenbonds to form secondary structure (see, e.g., U.S. Published PatentApplication No. 2014/0068797 to Doudna et al., published 6 Mar. 2014,incorporated herein by reference in its entirety; see also Jinek M., etal., Science 337:816-21 (2012)). A Cas-dual-guide RNA is capable offorming a nucleoprotein complex with a cognate Cas protein, wherein thecomplex is capable of targeting a nucleic acid target sequencecomplementary to the spacer sequence.

As used herein, the term “cognate” typically refers to a Cas protein(e.g., CasM protein) and one or more polynucleotides (e.g., aCRISPR-CasM-associated cognate nucleic acid guide) capable of forming anucleoprotein complex for site-directed binding to a nucleic acid targetsequence complementary to the nucleic acid target binding sequencepresent in one of the one or more polynucleotides.

The terms “wild-type,” “naturally-occurring,” “native,” and “unmodified”are used herein to mean the typical (or most common) form, appearance,phenotype, or strain existing in nature; for example, the typical formof cells, organisms, characteristics, polynucicotides, proteins,macromolecular complexes, genes, RNAs, DNAs, or genomes as they occur inand can be isolated from a source in nature. The wild-type form,appearance, phenotype, or strain serve as the original parent before anintentional modification. Thus, mutant, variant, engineered,recombinant, and modified forms are not wild-type forms.

As used herein, the terms “engineered,” “genetically eruzineered,”“recombinant,” “modified,” and “non-naturally occurring” areinterchangeable and indicate intentional human manipulation.

“Covalent bond,” “covalently attached,” “covalently bound,” “covalentlylinked,” “covalently connected,” and “molecular bond” are usedinterchangeably herein, and refer to a chemical bond that involves thesharing of electron pairs between atoms. Examples of covalent bondsinclude, but are not limited to, phosphodiester bonds andphosphorothioate bonds.

“Non-covalent bond,” “non-covalently attached,” “non-covalently bound,”“non-covalently linked,” “non-covalent interaction,” and “non-covalentlyconnected” are used interchangeably herein, and refer to any relativelyweak chemical bond that does not involve sharing of a pair of electrons.Multiple non-covalent bonds often stabilize die conformation ofmacromolecules and mediate specific interactions between molecules.Examples of non-covalent bonds include, but are not limited to hydrogenbonding, ionic interactions (e.g., Na⁺Cl⁻), van der Waals interactions,and hydrophobic bonds.

As used herein, “hydrogen bonding,” “hydrogen base pairing,” and“hydrogen bonded” are used interchangeably and refer to canonicalhydrogen bonding and non-canonical hydrogen bonding including, but notlimited to, “Watson-Crick-hydrogen-bonded base pairs”(W-C-hydrogen-bonded base pairs or W-C hydrogen bonding);“Hoogsteen-hydrogen-bonded base pairs” (Hoogsteen hydrogen bonding); and“wobble-hydrogen-bonded base pairs” (wobble hydrogen bonding). W-Chydrogen bonding, including reverse W-C hydrogen bonding, refers topurine-pyrimidine base pairing, that is, adenine:thymine,guanine:cytosine, and uracil: adenine. Hoogsteen hydrogen bonding,including reverse Hoogsteen hydrogen bonding, refers to a variation ofbase pairing in nucleic acids wherein two nucleobases, one on eachstrand, are held together by hydrogen bonds in the major groove. Thisnon-W-C hydrogen bonding can allow a third strand to wind around aduplex and form triple-stranded helices. Wobble hydrogen bonding,including reverse wobble hydrogen bonding, refers to a pairing betweentwo nucleotides in RNA molecules that does not follow Watson-Crick basepair rules. There are four major wobble base pairs; guanine:uracil,inosine (hypoxanthine):uracil, inosine-adenine, and inosine-cytosine.Rules for canonical hydrogen bonding and non-canonical hydrogen bondingare known to those of ordinary skill in the art (see, e.g. The RNAWorld, Third Edition (Cold Spring Harbor Monograph Series), R. F.Gesteland, Cold Spring Harbor Laboratory Press, ISBN 978-0879697396(2005); The RNA World, Second Edition (Cold Spring Harbor MonographSeries), R. F. Gesteland, et al., Cold Spring Harbor Laboratory Press,ISBN 978-0879695613 (1999); The RNA World (Cold Spring Harbor MonographSeries), R. F. Gesteland, et al., Cold Spring Harbor Laboratory Press,ISBN 978-0879694562 (1993) (see, e.g., Appendix 1; Structures of BasePairs Involving at Least Two Hydrogen Bonds, I. Tinoco); Principles ofNucleic Acid Structure, W. Saenger, Springer International PublishingAG, ISBN 978-0-387-90761-1 (1988); Principles of Nucleic Acid Structure,First Edition, S. Neidle, Academic Press, ISBN 978-01236950791 (2007)).

“Connect,” “connected,” and “connecting” are used interchangeablyherein, and refer to covalent bond or a non-covalent bond between twomacromolecules (e.g., polynucleotides, proteins, and the like). Thus,CasM and a cognate nucleic acid guide are “connected” in a cognatenucleic acid guide/CasM complex.

As used herein, the tenns “nucleic acid,” “nucleic acid sequence,”“nucleotide sequence,” “oligonucleotide,” and “polynucleotide” areinterchangeable and refer to a polymeric form of nucleotides. Thenucleotides may be deoxyribonucleotides (DNA), ribonucleotides (RNA),analogs thereof, or combinations thereof, and may be of any length.Polynucleotides may perform any function and may have any secondary andtertiary structures. The terms encompass known analogs of naturalnucleotides and nucleotides that are modified in the base, sugar and/orphosphate moieties. Analogs of a particular nucleotide have the samebase-pairing specificity (e.g., an analog of A base pairs with T). Apolynucleotide may comprise one modified nucleotide or multiple modifiednucleotides. Examples of modified nucleotides include fluorinatednucleotides, methylated nucleotides, and nucleotide analogs. Nucleotidestructure may be modified before or after a polymer is assembled.Following polymerization, polynucleotides may be additionally modifiedvia, for example, conjugation with a labeling component or targetbinding component. A nucleotide sequence may incorporate non-nucleotidecomponents. The terms also encompass nucleic acids comprising modifiedbackbone residues or linkages, which are synthetic, naturally occurring,and non-naturally occurring, and have similar binding properties as areference polynucleotide (e.g., DNA or RNA). Examples of such analogsinclude, but are not limited to, phosphorothioates, phosphoramidates,methyl phosphonates, chiral-methyl phosphonates, 2-O-methylribonucleotides, peptide-nucleic acids (PNAs), Locked Nucleic Acid(LNA™) (Exigon, Inc., Woburn, Mass.) nucleosides, glycol nucleic acid,bridged nucleic acids, and morpholino structures.

Peptide-nucleic acids (PNAs) are synthetic homologs of nucleic acidswherein the polynucleotide phosphate-sugar backbone is replaced by aflexible pseudo-peptide polymer, Nucleobases are linked to the polymer.PNAs have the capacity to hybridize with high affinity and specificityto complementary sequences of RNA and DNA.

In phosphorothioate nucleic acids, the phosphorothicate (PS) bondsubstitutes a sulfur atom for a non-bridging oxygen in thepolynucleotide phosphate backbone. This modification makes theinternucleotide linkage resistant to nuclease degradation, in someembodiments, phosphorothioate bonds are introduced between the last 3 to5 nucleotides at the 5′-end or 3′-end sequences of a polynucleotidesequence to inhibit exonuclease degradation. Placement ofphosphorotbioate bonds throughout an entire oligonucleotide helps reducedegradation by nucleases as well.

Threose nucleic acid (TNA) is an artificial genetic polymer. Thebackbone structure of TNA comprises repeating threose sugars linked byphosphodiester bonds. TNA polymers are resistant to nucleasedegradation. TNA can self-assemble by base-pair hydrogen bonding intoduplex structures.

Linkage inversions can be introduced into polynucleotides through use of“reversed phosphoramidites” (see, e.g.,ucalgary.ca/dnalab/synthesis/-modifications/linkages). A 3′-3′ linkageat a terminus of a polynucleotide stabilizes the polynucleotide toexonuclease degradation by creating an oligonucleotide having two 5′-OHtermini but lacking a 3′-OH terminus. Typically, such polynucleotideshave phosphoramidite groups on the 5′-OH position and a dimethoxytrityl(DMT) protecting group on the 3′-OH position. Normally, the DMTprotecting group is on the 5″-OH and the phosphoramidite is on the3″-OH.

Polynucleotide sequences are displayed herein in the conventional 5′ to3′ orientation unless otherwise indicated.

As used herein, the term “complementatity” refers to the ability of anucleic acid sequence to form hydrogen bond(s) with another nucleic acidsequence (e.g., through traditional Watson-Crick base pairing). Apercent complementarity indicates the percentage of residues in anucleic acid molecule that can norm hydrogen bonds with a second nucleicacid sequence. When two polynucleotide sequences have 100%complementarity, the two sequences are perfectly complementary, i.e.,all of a first polynucleotide's contiguous residues hydrogen bond withthe same number of contiguous residues in a second polynucleotide.

As used herein, “binding” refers to a non-covalent interaction betweenmacromolecules (e.g., between a protein and a polynucleotide, between apolynucleotide and a polynucleotide, between a protein and a protein,and the like). Such non-covalent interaction is also referred to as“associating” or “interacting” (e.g, if a first macromolecule interactswith a second macromolecule, the first macromolecule binds to secondmacromolecule in a noncovalent manner). Some portions of a bindinginteraction may be sequence-specific (the terms “sequence-specificbinding,” “sequence-specifically bind,” “site-specific binding,” and“site specifically binds” are used interchangeably herein).Sequence-specific binding, as used herein, typically refers to one ormore cognate nucleic acid guides (i.e., NATNAs) capable of forming acomplex with a protein (e.g., a CasM protein) to cause the protein tobind a nucleic acid sequence (e.g, RNA or DNA sequence) comprising anucleic acid target sequence (e.g., a RNA or DNA target sequence)preferentially relative to a second nucleic acid sequence (e.g., asecond RNA or DNA sequence) without the nucleic acid target bindingsequence (e.g., the RNA or DNA target binding sequence). All componentsof a binding interaction do not need to be sequence-specific, such ascontacts of a protein with phosphate residues in a DNA backbone. Bindinginteractions can be characterized by a dissociation constant (Kd).“Binding affinity” refers to the strength of the binding interaction. Anincreased binding affinity is correlated with a lower Kd.

As used herein, a Cas protein (e.g., a CasM protein) is said to “target”a polynucleotide if a cognate nucleic acid/Cas protein nucleoproteincomplex associates with, binds and/or cleaves a polynueleotide at thenucleic acid target sequence within the polynueleotide.

As used herein, “single-strand break” (SSB) refers to cleavage of asingle strand of RNA or DNA. A “double-strand break” (DSB) refers toboth strands of a double-stranded segment of nucleic acid being severed.In some instances, if such a break occurs, one strand can be said tohave a “sticky end” wherein nucleotides are exposed and not hydrogenbonded to nucleotides on the other strand. In other instances, a “bluntend” can occur wherein both strands remain fully base paired with eachother.

As used herein, the term “recombination” refers to a process of exChangeof genetic information between two polynucleotides.

As used herein, “nucleic acid repair,” such as but not limited to DNArepair, encompasses any process whereby cellular machinery repairsdamage to a nucleic acid molecule contained in the cell. The damagerepaired can include single-strand breaks or double-strand breaks(DSBs). At least three mechanisms exist to repair DSBs:homology-directed repair (HDR), classical non-homologous end joining(e-NHEJ), and micro homology-mediated end joining (MMEJ), all definedbelow. “Nucleic acid repair” is also used herein to refer to nucleicacid repair resulting from human manipulation, wherein a target locus ismodified, e.g., by inserting, deleting, or substituting nucleotides, allof which represent forms of genome editing.

As used herein, the term “homology-directed repair” or “HDR” refers tonucleic acid repair that takes place in cells, for example, duringrepair of double-strand and single-strand breaks in a nucleic acidmolecule, such as DNA. HDR requires, nucleotide sequence homology anduses a “donor template” (donor template nucleic acid, such as DNA,polynucleotide donor, or oligonucleotide (used interchangably herein) torepair the sequence where the double-strand break occurred (e.g., DNAtarget sequence). This results in the transfer of genetic informationfrom, for example, the donor template DNA to the DNA target sequence.HDR may result in alteration of the nucleic acid target sequence (e.g.,insertion, deletion, mutation) if the donor template sequence oroligonucleotide sequence differs from the target sequence and part orall of the donor template polynucleotide or oligonucleotide isincorporated into the target sequence. In some embodiments, an entiredonor template polynucleotide, a portion of the donor templatepolynucleotide, or a copy of the donor polynucleotide is copied orintegrated at the site of the target sequence.

By “donor polynucleotide” is meant a polynucleotide that can be directedto, and inserted into a target site of interest, such as an integrationlocus, to modify the target nucleic acid. All or a portion of the donorpolynucleotide can be inserted into the target nucleic acid. The donorpolynucleotide can be used for repair of the break in the target nucleicacid sequence resulting in the transfer of genetic information (i.e.,polynucleotide sequences) from the donor at the site or in closeproximity of the break. Accordingly, new genetic information (i.e.,polynucleotide sequences) may be inserted or copied at a target site.The donor polynucleotide can be double- or single-strand RNA, DNA, avector, plasmid, or the like. Thus, a donor polynucleotide can be an,insertion cassette, a recombinase expression vector, and the like.Non-symmetrical polynucleotide donors can also be used that are composedof two oligonucleotides. They are partially complementary, and each caninclude a flanking region of homology. The donor can be used to insertor replace polynucleotide sequences in a target sequence, for example,to introduce a polynucleotide that encodes a protein or functional RNA(e.g., siRNA), to introduce a protein tag, to modify a regulatorysequence of a gene, or to introduce a regulatory sequence to a gene(e.g. a promoter, an enhancer, an internal ribosome entry sequence, astart codon, a stop codon, a localization signal, or polyadenylationsignal), to modify a nucleic acid sequence (e.g., introduce a mutation),and the like.

Targeted nucleic acid modifications using donor polynucleotides forlarge changes (e.g., more than 100 base pair (bp) insertions ordeletions) traditionally use plasmid-based donor templates that containhomology arms flanking the site of alteration. Each arm can vary inlength, but is typically longer than about 100 bp, such as 100-1500 bp,e.g., 100 . . . 200 . . . 300 . . . 400 . . . 500 . . . 600 . . . 700 .. . 800 . . . 900 . . . 1000 . . . 1500 by or any integer between thesevalues. However, these numbers can vary, depending on the size of thedonor polynucleotide and the target polynucleotide. This method can beused to generate large modifications, including insertion of reportergenes such as fluorescent proteins or antibiotic resistance markers. Fortransfection in cells, such as HEK cells, approximately 100-1000nanograms (ng), 100 . . . 200 . . . 300 . . . 400 . . . 500 . . . 600 .. . 700 . . . 800 . . . 900 . . . 1000 ng or any integer between thesevalues, of a typical size donor plasmid (e.g., approximately 5 kb)containing a NATNA/Cas vector, can be used for one well in 24-wellplate. (See, e.g., Yang et al., “One Step Generation of Mice CarryingReporter and Conditional Alleles by CRISPR/Cas-Mediated GenomeEngineering” Cell (2013) 154:1370-1379).

Single-stranded and partially double-stranded oligonucleotides, such asDNA oligonucleotides, have been used in place of targeting plasmids forshort modifications (e.g., less than 50 bp) iNithin a defined locuswithout cloning. To achieve high HDR efficieiicies, single-strandedoligonucleotides containing flanking sequences on each side that arehomologous to the target region can be used, and can be oriented ineither the sense or antisense direction relative to the target locus.The length of each arm can vary, but the length of at least one arm istypically longer than about 10 bases, such as from 10-150 bases, e.g.,10 . . . 20 . . . 30 . . . 40 . . . 50 . . . 60 . . . 70 . . . 80 . . .90 . . . 100 . . . 110 . . . 120 . . . 130 . . . 140 . . . 150, or anyinteger within these ranges. However, these numbers can vary, dependingon the size of the donor polynucleotide and the target polynucleotide.In some embodiments, the length of at least one arm is 10 bases or more.In other embodiments, the length of at least one arm is 20 bases ormore. In yet other embodiments, the length of at least one arm is 30bases or more. In some embodiments, the length of at least one arm isless than 100 bases. In further embodiments, the length of at least onearm is greater than 100 bases. In some embodiments, the length of atleast one arm is zero bases. For single-stranded oligonucleotide design,typically an oligonueleotide with around 100-150 bp total homology isused. The mutation is introduced in the middle, giving 50-75 bp homologyarms for a donor designed to be symmetrical about the target site. Inother cases, no homology arms are required, and the donor polynucleotideis inserted using non-homologous repair mechanisms.

A “genomic region” is a segment of a chromosome in the genome of a hostcell that is present on either side of the nucleic acid target sequencesite or, alternatively, also includes a portion of the nucleic acidtarget sequence site. The homology arms of the donor polynucleotidc havesufficient homology to undergo homologous recombination with thecorresponding genomic regions. In some embodiments, the homology arms ofthe donor polynucleotide share significant sequence homology to thegenornic region immediately flanking the nucleic acid target sequencesite; it is recognized that the homology arms can be designed to havesufficient homology to genomic regions farther from the nucleic acidtarget sequence site.

As used herein the terms “classical non-homologous end joining” or“c-NREJ” refer to the repair of double-strand breaks in DNA by directligation of one end of the break to the other end of the break without arequirement for a donor template DNA. NHEJ in the absence of a donortemplate DNA often results in small insertions or deletions ofnucleotides at the site of the double-strand break, also referred to as“indels.” This DNA repair pathway is genetically defined and requiresthe activity of Ligase IV, DNA-PKes, Polμ, Polμ, and the Ku70/80heterodimer, among other proteins (see, e.g., Sfeir and Symington,Trends Biochem Sci (2015) 40:701-714).

“Microhomology-mediated end joining (MMEJ),” a form of alternativenonhomologous end-joining (alt-NHEJ), is another pathway for repairingdouble-strand breaks in DNA. MMEJ is associated with deletions flankinga DSB and involves alignment of microhomologous sequences internal tothe broken ends before joining. The proposed mechanism entails 5′-3′resection of the DNA ends at a DSB, annealing of the microhomologies(1-16 nucleotides of homology), removal of heterologous flaps, gapfilling DNA synthesis, and ligation. MMEJ is genetically defined andrequires the activity of CtlP, PARP1, Polθ, Lig1 and Lig3, among otherproteins (see, e.g., Sfeir and Symington, “Microhomology-Mediated EndJoining: A Back-up Survival Mechanism or Dedicated Pathway?” TrendsBiochem Sci (2015) 40:701-714).

Alternative mechanisms of nucleic acid insertion that do not requiresequence homology between the donor and the target sequence can also beused for nucleic acid insertion. These mechanisms involve variouscomponents of the cellular repair machinery and it is to be understoodthat the scope of the invention is not bound by the use of anyparticular mechanism for insertion of nucleic acid after target nucleicacid is cut or nicked by a site-specific polynucleotide.

“Gene,” as used herein, refers to a polynucleotide sequence comprisingexon(s) and related regulatory sequences. A gene may further compriseintron(s) and/or untranslated region(s) (UTR(s)).

As used herein, “expression” refers to transcription of a polynucleotidefrom a DNA template, resulting in, for example, a messenger RNA (mRNA)or other RNA transcript (e.g., non-coding, such as structural orscaffolding RNAs). The term further refers to the process through whichtranscribed mRNA is translated into peptides, polypeptides, or proteins.Transcripts and encoded polypeptides may be referred to collectively as“gene product(s).” Expression may include splicing the mRNA in aeukaryotic cell, if the polynucleotide is derived from genomic DNA.

As used herein, the term “modulate” refers to a change in the quantity,degree or amount of a function. For example, a cognate nucleic acidguide/CasM protein complex, as disclosed herein, may modulate theactivity of a promoter sequence by binding to a nucleic acid targetsequence at or near the promoter. Depending on the action occurringafter binding, the cognate nucleic acid guide/CasM protein complex caninduce, enhance, suppress, or inhibit transcription of a geneoperatively linked to the promoter sequence. Thus, “modulation” of geneexpression includes both gene activation and gene repression.

Modulation can beassayed by determining any characteristic directly orindirectly affected by the expression of the target gene. Suchcharacteristics include, e.g., changes in RNA or protein levels, proteinactivity, product levels, expression of the gene, or activity level ofreporter genes. Accordingly, the terms “modulating expression,”“inhibiting expression,” and “activating expression” of a gene can referto the ability of a cognate guidelCasM protein complex to change,activate, or inhibit transcription of a gene.

The terms “vector” and “plasmid” are used interchangeably and as usedherein refer to a polynucleotide vehicle to introduce genetic materialinto a cell. Vectors can be linear or circular. Vectors can integrateinto a target genome of a host cell or replicate independently in a hostcell. Vectors can comprise, for example, an origin of replication, amulticloning site, and/or a selectable markerAn expression vectortypically comprises an expression cassette. Vectors and plasmidsinclude, but are not limited to, integrating vectors, prokaryoticplasmids, eukaryotic plasmids, plant synthetic chromosomes, episomes,viral vectors, cosmids, and artificial chromosomes. An expression vectortypically comprises an expression cassette.

As used herein the term “expression cassette” is a polynucleotideconstruct, generated recombinantly or synthetically, comprisingregulatory sequences operably linked to a selected polynucleotide tofacilitate expression of the selected polynucleotide in a host cell Forexample, the regulatory sequences can facilitate transcription of theselected polynucleotide in a host cell, or transcription and translationof the selected polynucleotide in a host cell. An expression cassettecan, for example, be integrated in, the gnome of a host cell or bepresent in a vector to form an expression vector.

As used herein, a “targeting vector” is a recombinant DNA or RNAconstruct typically comprising tailored DNA or RNA arms, homologous togenomic DNA or RNA derived therefrom, that flank elements of a targetgene or nucleic acid target sequence (e.g., a SSB or DSB). A targetingvector comprises a donor polynucleotide. Elements of the target sequencecan be modified in a number of ways including deletions andiorinsertions. A defective target gene can be replaced by a functionaltarget gene, or in the alternative a functional gene can be knocked out.Optionally, the donor polynucleotide of a targeting vector comprises aselection cassette comprising a selectable marker that is introducedinto the target gene. Targeting regions (i.e., nucleic acid targetsequences) adjacent or within a target gene or region can be used toaffect regulation of gene expression.

As used herein, the terms “regulatory sequences,” “regulatory elements,”and “control elements” are interchangeable and refer to polynueleotidesequences that are upstream (5′ non-coding sequences), within, ordownstream (3 non-translated sequences) of a polynucleotide target to beexpressed. Regulatory sequences influence, for example, the timing oftranscription, amount or level of transcription, RNA processing orstability, and/or translation of the related structural nucleotidesequence. Regulatory sequences may include activator binding sequences,enhancers, introns, polyadenylation recognition sequences, promoters,transcription start sites, repressor binding sequences, stem-loopstructures, translational initiation sequences, internal ribosome entrysites (IRES), translation leader sequences, transcription terminationsequences (e.g., polyadenylation signals and poly-U sequences),translation tennination sequences, primer binding sites, and the like.

Regulatory elements include those that direct constitutive, inducible,and repressible expression of a nucleotide sequence in many types ofhost cells and those that direct expression of the nucleotide sequenceonly in certain host cells (e.g., tissue-specific regulatory sequences).In some embodiments, a vector comprises one or more pol III promoters,one or more pol II promoters, one or more pol I promoters, orcombinations thereof Examples of pol II promoters include, but are notlimited to, U6 and H1 promoters. Examples of pol II promoters include,but are not limited to, the retroviral Rous sarcoma virus (RSV) LTRpromoter (optionally with the RSV enhancer), the cytomegalovirus (CMV)promoter (optionally with the CMV enhancer; see, e.g., Boshart, M., etal., Cell 41:521-530 (1985)), the SV40 promoter, the dihydrofolatereductase promoter, the β-actin promoter, the phosphoglycerol kinase(PGK) promoter, and the EF1α promoter. It will be appreciated by thoseskilled in the art that the design of an expression vector may depend onsuch factors as the choice of the host cell to be transformed, the levelof expression desired, and the like. A vector can be introduced intohost cells to thereby produce transcripts, proteins, or peptides,including fusion proteins or peptides, encoded by nucleic acids asdescribed herein.

As used herein the term “operably linked” refers to polynucleotidesequences or amino acid sequences placed into a functional relationshipwith one another. For instance, a promoter or enhancer is operablylinked to a coding sequence if it regulates, or contributes to themodulation of, the transcription of the coding sequence. Operably linkedDNA sequences encoding regulatory sequences arc typically contiguous tothe coding sequence. However, enhancers can function when separated froma promoter by up to several kilohases or more. Accordingly, somepolynucleotide elements may be operably linked but not contiguous.

As used herein, the term “expression” refers to transcription of apolynucicatide from a DNA template, resulting in, for example, an mRNAor other RNA transcript (e.g., non-coding, such as structural orscaffolding RNAs). The term further refers to the process through whichtranscribed mRNA is translated into peptides, polypeptides, or proteins.Transcripts and encoded polypeptides may be referred to collectively as“gene product.” Expression may include splicing the mRNA in a eukaryoticcell, if the polynucleotide is derived from genomic DNA.

As used herein, the term “sequence identity” generally refers to thepercent identity of bases or amino acids determined by comparing a firstpolynucleotide or polypeptide to a second polynucleotide rpolypeptideusing algorithms having various weighting parameters. Sequence identitybetween two polypeptides or two polynucleotides can be determined usingsequence alignment by various methods and computer programs (e.g.,BLAST, CS-BLAST, FASTA, HMMER, L-ALIGN, etc.), available through theworldwide web at sites including GENBANK (ncbi.nlm.nih.gov/genbank/) andEMBL-EBI (ebi.ac.uk.). Sequence identity between two polynucleotides ortwo polypeptide sequences is generally calculated using the standarddefault parameters of the various methods or computer programs.Generally, Cas proteins, such as CasM homologs, for use herein will haveat least about 75% or more sequence identity to the wild-type ornaturally occurring sequence of the Cas protein of interest, such asabout 80%, such as about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99%, or complete identity. CasM orthologs can vary widely from thereference sequence. For example, CasM orthologs shown in Table 1 displayapproximately 13.59% to 99.82% sequence identity to each other. Thus,CasM orthologs are identified based on the CasM characteristics detailedherein.

As used herein, “hybridization,” “hybridize,” or “hybridizing” is theprocess of combining two complementary single-stranded DNA or RNAmolecules so as to form a single double-stranded molecule (DNA/DNA,DNA/RNA, RNA/RNA) through hydrogen base pairing. Hybridizationstringency is typically determined by the hybridization temperature andthe salt concentration of the hybridization buffer; e.g., hightemperature and low salt provide high stringency hybridizationconditions. Examples of salt concentration ranges and temperature rangesfor different hybridization conditions are as follows: high stringency,approximately 0.01M to approximately 0.05M salt, hybridizationtemperature 5° C. to 10° C. below T_(m); moderate stringency,approximately 0.16M to approximately 0.33M salt, hybridizationtemperature 20° C. to 29° C. below T_(m); and low stringency,approximately 0.33M to approximately 0.82M salt, hybridizationtemperature 40° C. to 48° C. below T_(m). T_(m) of duplex nucleic acidsis calculated by standard methods well-known in the art (see, e.g.,Maniatis, T., et al., Molecular Cloning; A Laboratory Manual, ColdSpring Harbor Laboratory Press: New York (1982); Casey, J., et al.,Nucleic Acids Research 4:1539-1552 (1977); Bodkin, D. K., et al.,Journal of Virological Methods 10(1):45-52 (1985); Wallace, R. B., etal., Nucleic Acids Research 9(4):879-894 (1981)). Algorithm predictiontools to estimate T_(m) are also widely available. High stringencyconditions for hybridization typically refer to conditions under which apolynucleotide complementary to a target sequence predominantlyhybridizes with the target sequence, and substantially does nothybridize to non-target sequences. Typically, hybridization conditionsare of moderate stringency, preferably high stringency.

As used herein, the term “amino acid” refers to natural and synthetic(unnatural) amino acids, including amino acid analogs, modified aminoacids, peptidamimetics, glycine, and D or L optical isomers.

As used herein, the terms “peptide,” “polypeptide,” and “protein” areinterchangeable and refer to polymers of amino acids. A polypeptide maybe of any length. It may be branched or linear, it may be interrupted bynon-amino acids, and it may comprise modified amino acids. The terms maybe used to refer to an amino acid polymer that has been modifiedthrough, for example, acetylation, disulfide bond formation,glycosylation, lipidation, phosphorylation, cross-linking, and/orconjugation (e.g., with a labeling component or ligand). Polypeptidesequences are displayed herein in the conventional N-terminal toC-terminal orientation.

Polypeptides and polynucleotides can be made using routine techniques inthe field of molecular biology (see, e.g., standard texts set forthabove). Further, essentially any polypeptide or polymicleotide can becustom ordered from commercial sources.

The terms “fusion protein” and “chimeric protein,” as used herein, referto a single protein created by joining two or more proteins, proteindomains, or protein fragments that do not naturally occur together in asingle protein. For example, a fusion protein can contain a first domainfrom a CasM protein and a second domain from a different Cas protein.The modification to include such domains in fusion proteins may conferadditional activity on the modified site-directed polypeptides. Suchactivities can include nuclease activity, methyltransferase activity,demethylase activity, DNA or RNA repair activity, DNA or RNA damageactivity, deamination activity, dismutase activity, alkylation activity,depurination activity, oxidation activity, pyrimidine dimer formingactivity, integrase activity, transposase activity, recombinaseactivity, polymerase activity, ligase activity, helicase activity,photolyase activity, glycosylase activity, acetyltransferase activity,deacetylase activity, kinase activity, phosphatase activity, ubiquitinligase activity, deubiquitinating activity, adenylation activity,deadenylation activity, SUMOylating activity, deSUMOylating activity,ribosylation activity, deribosylation activity, myristoylation activity,or demyristoylation activity) that modifies a polypeptide associatedwith nucleic acid target sequence (e.g., a histone) A fusion protein canalso comprise epitope tags (e.g., histidine tags, FLAG® (Sigma Aldrich,St. Louis, Mo.) tags, Myc tags), reporter protein sequences (e.g.,glutathione-S-transferase, beta-galactosidase, luciferase, greenfluorescent protein, cyan fluorescent protein, yellow fluorescentprotein), and/or nucleic acid binding domains (e.g., a DNA bindingdomain, an RNA binding domain). A fusion protein can also compriseactivator domains (e.g., heat shock transcription factors, NFKBactivators) or repressor domains (e.g., a KRAB domain). As described byLupo, A. et al., Current Genomics 14(4): 268-278 (2013), the KRAB domainis a potent transcriptional repression module and is located in theamino-terminal sequence of most C2H2 zinc finger proteins (see, e.g.,Margolin, J., et al., Proceedings of the National Academy of Sciences ofthe United States of America 91:4509-4513 (1994); Witzgall, R., et al.,Proceedings of the National Academy of Sciences of the United States ofAmerica 91:4514-4518 (1994)). The KRAB domain typically binds toco-repressor proteins and/or transcription factors via protein-proteininteractions, causing transcriptional repression of genes to which KRABzinc finger proteins (KRAB-ZFPs) bind (see, e.g., Friedman J. R., etal., Genes & Development 10:2067-2678 (1996)). In some embodiments,linker nucleic acid sequences are used to join the two or more proteins,protein domains, or protein fragments,

A “moiety,” as used herein, refers to a portion of a molecule. A moietycan be a functional group or describe a portion of a molecule withmultiple functional groups (e.g., that share common structural aspects).The terms “moiety” and “functional group” are typically usedinterchangeably; however, a “functional group” can more specificallyrefer to a portion of a molecule that comprises some common chemicalbehavior. “Moiety” is often used as a structural description. In someembodiments, a 5′ terminus, a 3′ terminus, or a 5′ terminus and a 3′terminus (e.g., a non-native 5′ terminus and/or a non-native 3′ terminusin a first stem element) can comprise one or more moieties.

As used herein, the term “isolated” can refer to a nucleic acid orpolypeptide that, by the hand of a human, exists apart from its nativeenvironment and is therefore not a product of nature. Isolated meanssubstantially pure. An isolated nucleic acid or polypeptide can exist ina purified form and/or can exist in a non-native environment such as,for example, in a recombinant cell.

As used herein, a “host cell” generally refers to a biological cell. Acell is the basic structural, functional and/or biological unit of anorganism. A cell can originate from any organism having one or morecells. Examples of host cells include, but are not limited to: aprokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, acell of a single-cell eukaryotic organism, a protozoal cell, a cell froma plant (e.g., cells from plant crops (such as soy, tomatoes, sugarbeets, pumpkin, bay, cannabis, tobacco, plantains, yams, sweet potatoes,cassava, potatoes, wheat, sorghum, soybean, rice, corn, maize,oil-producing Brassica (e.g., oil-producing rapeseed and canola),cotton, sugar cane, sunflower, millet, and alfalfa), fruits, vegetables,grains, seeds, flowering plants, conifers, gymnosperms, ferns,clubmosses, hornworts, liverworts, mosses), an algal cell, (e.g.,Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsisgaditana, Chlorella pyrenoidosa,Sargassum patens C. agardh, and thelike), seaweeds (e.g., kelp), a fungal cell (e.g., a yeast cell or acell from a mushroom), an animal cell, a cell from an invertebrateanimal (e.g., fruit fly, cnidarian, echinoderm, nematode, and the like),a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird,or mammal), a cell from a mammal (e.g., a pig, a cow, a goat, a sheep, arodent, a rat, a mouse, a non-human primate, a human, and the like).Furthermore, a cell can be a stem cell or a progenitor cell.

As used herein, “stem cell” refers to a cell that has the capacity forself-renewal, i.e., the ability to go through numerous cycles of celldivision while maintaining the undifferentiated state. Stem cells can betotipotent, pluripotent, multipotent, oligopotent, or unipotent. Stemcells can be embryonic, fetal, amniotic, adult, or induced pluripotentstem cells.

As used herein, “induced pluripotent stem cells” refers to a type ofpluripotent stem cell that is artificially derived from anon-pluripotent cell, typically an adult somatic cell, by inducingexpression of specific genes.

“Plant,” as used herein, refers to whole plants, plant organs, planttissues, germplasm, seeds, plant cells, and progeny of the same. Plantcells include, without limitation, cells from seeds, suspensioncultures, embryos, meristematic regions, callus tissue, leaves, roots,shoots, gametophytes, sporophytes, pollen, and microspores. Plant partsinclude differentiated and undifferentiated tissues including, but notlimited to roots, stems, shoots, leaves, pollens, seeds, tumor tissue,and various forms of cells and culture (e.g., single cells, protoplasts,embryos, and callus tissue). The plant tissue may be in plant or in aplant organ, tissue or cell culture, “Plant organ” refers to planttissue or a group of tissues that constitute a morphologically andfunctionally distinct part of a plant.

“Subject,” as used herein, refers to any member of the phylum Chordata,including, without limitation, humans and other primates; includingnon-human primates such as rhesus macaques, chimpanzees and other monkeyand ape species; farm animals, such as cattle, sheep, pigs, goats, andhorses; domestic mammals, such as dogs and cats; laboratory animals,including rabbits, mice, rats, and guinea pigs; birds, includingdomestic, wild, and game birds, such as chickens, turkeys, and othergallinaceous birds, ducks, and geese; and the like. The term does notdenote a particular age or gender. Thus, the term includes adult, young,and newborn individuals as well as male and female. In some embodiments,a host cell is derived, from a subject (e.g., stem cells, progenitorcells, or tissue-specific cells). In some embodiments, the subject is anon-human subject.

As used herein, “transgenic organism” refers to an organism whose genomeis genetically modified. The term includes, the progeny (any generation)of a transgenic organism, provided that the progeny has the geneticmodification.

CRISPR Systems

The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)genomic locus is found in the genomes of many prokaryotes (e.g.,bacteria and archaea). CRISPR loci provide resistance to foreigninvaders (e.g., virus, phage) in prokaryotes. In this way, the CRISPRsystem functions as a type of immune system to help defend prokaryotesagainst foreign invaders. There are three main stages in CRISPR-Casimmune systems; (1) acquisition, (2) expression, and (3) interference.Acquisition involves cleaving the genome of invading viruses andplasmids and integrating segments (termed protospacers) of the genomicDNA into the CRISPR locus of the host organism. The segments that areintegrated into the host genome are known as spacers, which mediateprotection from subsequent attack by the same (or sufficiently related)virus or plasmid. Expression involves transcription of the CRISPR locusand subsequent enzymatic processing to produce short mature CRISPR RNAs,each containing a single spacer sequence. Interference is induced afterthe CRISPR RNAs associate with Cas proteins to form of complexes, whichare then targeted to complementary protospacers in foreign geneticelements to induce nucleic acid degradation.

Currently, two classes of CRISPR systems have been described, Class 1and Class 2, based upon the genes encoding the effector module, i.e.,the proteins involved in the interference stage. Class 1 systems have amulti-subunit crRNA-effector complex, whereas Class 2 systems have asingle protein, such as Cas9, Cpf1, C2c1, C2c2, C2c3, or acrRNA-effector complex. Class 1 systems comprise Type I, Type III andType IV systems, Class 2 systems comprise Type II, Type V and Type VIsystems.

To date, there are six types (Types I-VI) and 19 subtypes of CRISPRsystems categorized within these classes (Makarova et al, Nature ReviewsMicrobiology (2015) 13:1-15; Shmakov et al., Nature Reviews Microbiology(201) 15:169-182).

CRISPR loci are currently characterized as including a number of shortrepeating sequences referred to as “repeats.” Repeats can form hairpinstructures andior repeats can be unstructured single-stranded sequences.The repeats occur clusters. Repeats frequently diverge between species.Repeats are regularly interspaced with unique intervening sequences,referred to as “spacers,” resulting in a repeat-spacer-repeat locusarchitecture. Spacers are identical to or are homologous with knownforeign invader sequences. In some instances, a spacer-repeat unitencodes a crisprRNA (crRNA). A crRNA refers to the mature form of thespacer-repeat unit. A crRNA contains a spacer sequence that is involvedin targeting a target nucleic acid (e.g., possibly as a surveillancemechanism against foreign nucleic acid). Thus, crRNA has a region ofcomplementarity to a potential DNA or RNA target sequence and in somecases, e.g., in currently characterized Type II systems, a second regionthat forms base-pair hydrogen bonds with a transactivating CRISPR RNA(traerRNA) to form a secondary structure, typically to form at least astem structure. In this context, the tracrRNA and a crRNA interactthrough a number of base-pair hydrogen bonds to form secondary RNAstructures. Complex formation between tracrRNA/crRNA and a Cas proteinresults in conformational change of the Cas protein that facilitatesbinding to DNA, nuclease activities of the Cas protein, and crRNA-guidedsite-specific DNA cleavage by the nuclease. For a CasproteinitracrRNA/crRNA complex to cleave a DNA target sequence, the DNAtarget sequence is adjacent to a cognate protospaeer adjacent motif(PAM).

A CRISPR locus comprises polynucleotide sequences encoding for CRISPRAssociated Genes (cas) genes. Cas genes are involved in the biogenesisand/or the interference stages of crRNA function. Cas genes displayextreme sequence (e.g., primary sequence) divergence between species andhomologs. Some Cas genes comprise homologous secondaty and/or tertiarystructures. Cas genes are typically named according to the organism fromwhich they are derived. For example, Cas genes in Staphylococcusepidermidis can be referred to as Csm-type, Cas genes in Streptococcusthermnophilus can be referred to as Csn-type, and Cas genes inPyrococcus furiosus can be referred to as Cmr-type.

The integration stage of a CRISPR system refers to the ability of theCRISPR locus to integrate new spacers into the crRNA array upon beinginfected by a foreign invader. Acquisition of the foreign invaderspacers can help confer immunity to subsequent attacks by the sameforeign invader. Integration typically occurs at the leader end of theCRISPR locus. Cas proteins are involved in integration of new spacersequences. Integration proceeds similarly for some types of CRISPRsystems (e.g., Types I-III).

Mature crRNAs are processed from a longer polycistronic CRISPR, locustranscript pre-crRNA array). A pre-crRNA array comprises a plurality ofcrRNAs. The repeats in the pre-crRNA array are recognized by cas genes.Cas genes bind to the repeats and cleave the repeats. This action canliberate the plurality of crRNAs, crRNAs can be subjected to furtherevents to produce the mature crRNA form such as trimming (e.g., with anexonuclease). A crRNA may comprise all, some, or none of the CRISPRrepeat sequence.

Interference refers to the stage in the CRISPR system that isfunctionally responsible for combating, infection by a foreign invader.CRISPR interference follows a similar mechanism to RNA interference(RNAi: e.g., wherein a target RNA is targeted (e.g., hybridized) by ashort interfering RNA (siRNA)), which results in target RNA degradationand/or destabilization. Currently characterized CRISPR systems performinterference of a target nucleic acid by coupling crRNAs and Cas genes,thereby forming CRISPR ribonucleoproteins (RNPs). crRNA of the RNPguides the RNP to foreign invader nucleic acid, (e.g., by recognizingthe foreign invader nucleic acid through hybridization). Hybridizedtarget foreign invader nucleic acid-crRNA units are subjected tocleavage by Cas proteins. Target nucleic acid interference typicallyrequires a protospacer adjacent motif (PAM) in a target nucleic acid.

By a “CRISPR-Cas system” as used herein, is meant any of the variousCRISPR-Cas classes, types, and subtypes. Class I systems comprise TypeI, Type III, and Type IV systems. Type I systems are currentlycharacterized as having a Cas3 protein that has helicase activity andcleavage activity. Type I systems are further divided into severalsubtypes that have a defined combination of signature genes and distinctfeatures of operon organization.

To date, it appears that all Type III systems possess a cas10 gene,which encodes a muitidomain protein containing a Palm domain (a variantof the RNA recognition motif (RRM)) that is homologous to the coredomain of numerous nucleic acid polymerases and cyclases and that is thelargest subunit of Type III crRNA-effector complexes. All Type III locialso encode the small subunit protein, one Cas5 protein and typicallyseveral Cas7 proteins. Type III is also further divided into severalsubtypes.

Type IV systems encode a minimal multisubunit crRNA-effector complexcomprising a partially degraded large subunit, Csf1, Cas5, Cas7, and insome cases, a putative small subunit Type IV systems lack cas1 and cas2genes. Type IV systems do not have subtypes, but there are two distinctvariants. One Type IV variant has a DinG family helicase, whereas asecond Type IV variant lacks a Dine; family her ease, but has a geneencoding a small α-helical protein. An example of an organism with aType IV system is Acidithiobacillus ferrooxidans.

Class 2 systems comprise Type II, Type V, and Type VI systems. Type IIsystems include cas1, cas2 and cas9 genes. There are two strands of RNAin Type II systems, a crRNA and a tracrRNA, that hybridizes to acomplementary region of pre-crRNA causing maturation of the pre-crRNA tocrRNA. The duplex formed by the tract-RNA and crRNA is recognized by,and associates with a multidomain protein, Cas9, encoded by the cas9gene, which combines the functions of the crRNA-effector complex withtarget DNA cleavage. Cas9 is directed to a target nucleic acid by asequence of the crRNA, that is complementary to, and hybridizes with, asequence in the target nucleic acid.

In Type V systems, nucleic acid target sequence binding involves aCas12a protein and the crRNA, as does the nucleic acid target sequencecleavage. In Type V systems, the RuvC-like nuclease domain of Cas12aprotein cleaves both strands of the nucleic acid target sequence in asequential fashion (Swarts, et al., Mol. Cell (2017) 66:221-233.e4),producing 5′ overhangs, which contrasts with the blunt ends generated byCas9 protein cleavage.

The Cas12a protein cleavage activity of Type V systems does not requirehybridization of crRNA to tracrRNA to form a duplex; rather Type Vsystems use a single crRNA that has a stem-loop structure forming aninternal duplex. Cas12a protein binds the crRNA in a sequence-andstructure-specific manner by recognizing the stem loop and sequencesadjacent to the stem loop, most notably the nucleotides 5′ of the spacersequence, which hybridizes to the nucleic acid target sequence. Thisstem-loop structure is typically in the range of 15 to 19 nucleotides inlength. Substitutions that disrupt this stem-loop duplex abolishcleavage activity, whereas other substitutions that do not disrupt thestem-loop duplex do not abolish cleavage activity.

Type VI systems include the Cas13a protein (also known as Class 2candidate 2 protein, or C2c2) which does not share sequence similaritywith other CRISPR effector proteins (see Abudayyeh, et al Science (2016)353:aaf5573). Cas 13a proteins have two HEPN domains and possesssingle-stranded RNA cleavage activity. Cas13a proteins are similar toCas12a proteins in requiring a crRNA for nucleic acid target sequencebinding and cleavage, but not requiring tracrRNA. Also, similar toCas12a protein, the crRNA for Cas13a proteins forms a stable hairpin, orstem-loop structure, that aids in association with the Cas 13a protein.Type VI systems have a single polypeptide RNA endonuclease that utilizesa single crRNA to direct RNA cleavage in a target-dependent fashion.Additionally, after hybridizing to the target RNA complementary to thespacer, Cas13a protein becomes a promiscuous RNA endonuclease exhibitingnon-specific endonuclease activity toward any single-stranded RNA in asequence independent manner (see East-Seletsky, et al., Nature (2016)538:270-273).

As is readily apparent, the discovery and characterization of CRISPRsystems is currently evolving.

Production of CRISPR Components

In all of the embodiments described herein, the various components canbe produced by synthesis, or for example, using expression cassettesencoding CasM, a cognate guide, etc. The various components can beprovided to a cell or used in vitro. These components can be present ona single cassette or multiple cassettes, in the same or differentconstructs. Expression cassettes typically comprise regulatory sequencesfunctional in host cells into which they are introduced. Regulatorysequences are involved in one or more of the following: regulation oftranscription, post-transcriptional regulation, and regulation oftranslation. Expression cassettes can be present in expression vectorsand introduced into a wide variety of host cells including bacterialcells, yeast cells, plant cells, and mammalian cells.

In one aspect, all or a portion of the various components for use hereinare produced in vectors, including expression vectors, comprisingpolynucleotides encoding therefor. Vectors useful for producingcomponents for use in the present methods include plasmids, viruses(including phage), and integratable nucleic acid fragments (i.e.,fragments integratable into the host genome by homologousrecombination). A vector replicates and functions independently of thehost genome, or may, in some instances, integrate into the genomeitself. Suitable replicating vectors will contain a replicon and controlsequences derived from species compatible with the intended expressionhost cell. In some embodiments, polynucleotides encoding one or more ofthe various components are operably linked to an inducible promoter, arepressible promoter, or a constitutive promoter. Expression vectors canalso include polynucleotides encoding protein tags (e.g., poly-His tags,hemagglutinin tags, fluorescent protein tags, bioluminescent tags,nuclear localization tags). The coding sequences for such protein tagscan be fused to the coding sequences or can be included in an expressioncassette, for example, in a targeting vector.

General methods for construction of expression vectors are known in theart. Expression vectors for most host cells are commercially available.There are several commercial software products designed to facilitateselection of appropriate vectors and construction thereof, such asinsect cell vectors for insect cell transformation and gene expressionin insect cells, bacterial plasmids for bacterial transformation andgene expression in bacterial cells, yeast plasmids for celltransformation and gene expression in yeast and other fungi, mammalianvectors for mammalian cell transformation and gene expression inmammalian cells or mammals, viral vectors (including retroviral,lentiviral, and adenoviral vectors) for cell transformation and geneexpression and methods to easily enable cloning of such polynucleotides.SnapGene™ (GSL Biotech LLC, Chicago, Ill.;snapgene.com/resources/plasmid_files/your_time_is_valuable/), forexample, provides an extensive list of vectors, individual vectorsequences, and vector maps, as well as commercial sources for many ofthe vectors.

Several expression vectors have been designed for expressing guidepolynucleotides. See, e.g., Shen et al. Nat. Methods (2014) 11:399-402.Additionally, vectors and expression systems are commercially available,such as from New England Biolabs (Ipswich, Mass.) and ClontechLaboratories (Mountain View, Calif.). Vectors can be designed tosimultaneously express a target-specific NATNA using a U2 or U6promoter, a CasM and/or dCasM, and if desired, a marker protein, formonitoring transfection efficiency and/or for furtherenriching/isolating transfected cells by flow cytometry.

For example, the various components can be incorporated into mammalianvectors for use in mammalian cells. A large number of mammalian vectorssuitable for use with the systems of the present invention arecommercially available (e.g., from Life Technologies, Grand Island,N.Y.; NeoBiolab, Cambridge, Mass.; Promega, Madison, Wisc.; DNA20, MenloPark, Calif.; Addgene, Cambridge, Mass.)

Vectors derived from mammalian viruses can also be used for expressingthe various components of the present methods in mammalian cells. Theseinclude vectors derived from viruses such as adenovirus papovirus,herpesvirus, polyomavirus, cytomegalovirus, lentivirus, retrovirus,vaccinia and Simian Virus 40 (SV40) (see, e.g., Kaufman, R. J., Molec.Biotech. (2000) 16:151-160; Cooray et al., Methods Enzymol. (2012)507:29-57). Regulatory sequences operably linked to the components caninclude activator binding sequences, enhancers, introns, polyadenylationrecognition sequences, promoters, repressor binding sequences, stem-loopstructures, translational initiation sequences, translation leadersequences, transcription termination sequences, translation terminationsequences, primer binding sites, and the like. Commonly used promotersare constitutive mammalian promoters CMV, EF1a, SV40, PGK1 (mouse orhuman), Ubc, CAG, CaMKIIa, and beta-Act, and others known in the art(Khan, K. H. Advanced Pharmaceutical Bulletin (2013)3:257-263).Furthermore, mammalian RNA polymerase III promoters, including H1 andU6, can be used.

Numerous mammalian cell lines have been utilized for expression of geneproducts including HEK 293 (Human embryonic kidney) and CHO (Chinesehamster ovary). These cell lines can be transfected by standard methods(e.g., using calcium phosphate or polyethyleneimine (PEI), orelectroporation). Other typical mammalian cell lines include, but arenot limited to: HeLa, U2OS, 549, HT1080, CAD, P19, NiH 3T3, L929, N2a,Human embryonic kidney 293 cells, MCF-7, Y79, SO-Rb50, Hep G2, DUKX-X11,J558L; and Baby hamster kidney (BHK) cells.

Vectors can be introduced into and propagated in a prokaryote,prokaryotic vectors are well known in the art. Typically a prokaryoticvector comprises an origin of replication suitable for the target hostcell (e.g., oriC derived from E. coli, pUC derived from pBR322, pSC101derived from Salmonella), 15A origin (derived from p15A) and bacterialartificial chromosomes). Vectors can include a selectable marker (e.g.,genes encoding resistance for ampicillin, chlora.mphenicol, gentamicin,and kanamycin). Zeocin™ (Life Technologies, Grand Island, N.Y.) can beused as a selection in bacteria, fungi (including yeast), plants andmammalian cell lines. Accordingly, vectors can be designed that carryonly one drug resistance gene for Zeocin for selection work in a numberof organisms. Useful promoters are known for expression of proteins inprokaryotes, for example, T5, T7, Rhamnose (inducible), Arabinose(inducible), and PhoA (inducible). Furthermore, T7 promoters are widelyused in vectors that also encode the T7 RNA polymerase. Prokaryoticvectors can also include ribosome binding sites of varying strength, andsecretion signals (e.g., mal, sec, tat, ompC, and pelB). In addition,vectors can comprise RNA polymerase promoters for the expression ofNATNAs. Prokaryotic RNA polymerase transcription termination sequencesare also well known (e.g., transcription termination sequences fromStreptococcus pyogenes).

Expression of proteins in prokaryotes is typically carried out in E.coli with vectors containing constitutive or inducible promotersdirecting the expression of either fusion or non-fusion proteins.

In some embodiments, a vector is a yeast expression vector comprisingone or more components of the above-described methods. Examples ofvectors for expression in Saccharomyces cerivisae include, but are notlimited to, the following: pYepSec1, pMFa, pJRY88, pYES2, and picZ.Methods for gene expression in yeast cells are known in the art (see,e.g., Methods in Enzymology, Volume 194, “Guide to Yeast Genetics andMolecular and Cell Biology, Part A,” (2004) Christine Guthrie and GeraldR. Fink (eds.), Elsevier Academic Press, San Diego, Calif.). Typically,expression of protein-encoding genes in yeast requires a promoteroperably linked to a coding region of interest plus a transcriptionalterminator. Various yeast promoters can be used to construct expressioncassettes for expression of genes in yeast.

CasM Proteins

CasM, a new CRISPR-Cas protein, is described herein. CasM displaysnucleic acid binding activity and produces breaks, such as singe-strandbreaks (SSBs) or DSBs, when brought into proximity with a nucleic acidtarget sequence, e.g., by association with a cognate nucleic acid guide,such as a cognate crRNA. As shown in the Examples herein, CasM targetsRNA and is capable of cleaving ssRNA, such as when delivered to agenomic target when complexed with a crRNA, without the necessity ofassociation with a tracrRNA. CasM proteins typically include two or morehigher eukaryotic and prokaryotic nucleotide-binding (EPN)) domainsfound in protein family PF05168, in the C-terminal region of the CasMsequence. CasM proteins show synteny with one or more WYLdomain-containing proteins and sometimes with RtcB (RNA 3′-terminalphosphate cyclase, group B) domain-containing proteins. Based on theforegoing characteristics, CasM may be classified as a Class 2 Type VICRISPR-Cas system. However, CasM has a very low degree of sequencesimilarity to other Type VI subtypes.

Exemplary CasM proteins are shown in SEQ ID NOS:37-45, and are encodedby polynucleotides shown in SEQ ID NOS:28-36, respectively. Theseproteins display approximately 13.59% to 99.82% sequence identity toeach other and show less than 8% sequence identity with other knownCRISPR-Cas proteins. CasM has been found in several species and isolatesincluding, without limitation, Eubacterium siraeum; Ruminococcus sp.,such as from Ruminococcus bicirculans; Ruminococcus flavefaciens, suchas, but not limited to, FD-1 and strain XPD3002; Ruminococcus albus suchas, but not limited to, strain KH2T6; Ruminococcus sp. isolates, such asbut not limited to, isolates 2789STDY5834971, 2789STDY5608892 and2789STDY5834894. However, is it to be understood that the term “CasM”refers to a protein derived from any species, subspecies or strain ofbacteria that encodes a CasM protein, as well as orthologs thereof, orvariants thereof. Representative CasM proteins include, but are notlimited to, those proteins depicted as SEQ ID NOS:37-45 (see Table 1),orthologs thereof, or variants thereof. CasM proteins are approximately800 to approximately 1000 amino acids in length.

TABLE 1 Representative CasM Proteins Species/Isolate SEQ ID NOEubacterium siraeum SEQ ID NO: 37 Ruminococcus sp., isolate2789STDY5834971 SEQ ID NO: 38 Ruminococcus bicirculans SEQ ID NO: 39Ruminococcus sp., isolate 2789STDY5608892 SEQ ID NO: 40 Ruminococcus sp.CAG:57 SEQ ID NO: 41 Ruminococcus flavefaciens FD-1 SEQ ID NO: 42Ruminococcus albus strain KH2T6 SEQ ID NO: 43 Ruminococcus flavefaciensstrain XPD3002 SEQ ID NO: 44 Ruminococcus sp., isolate 2789STDY5834894SEQ ID NO: 45

Analysis of these CasM protein sequences indicates the presence of twoHEPN domains in the C-terminal region of the sequences. The HEPN domainis often involved in nucleic acid binding and can function as ametal-independent RNase in certain instances.

CasM systems display strong synteny with an open reading frame in WYLdomain-(protein family PF13280) containing proteins. The sequences forWYL domains in various species that encode CasM proteins are shown asSEQ ID NOS:52-59 (see Table 2). WYL domains share similarities withCRISPR-associated Rossman fold (CARF) domains and are thought to bindligands derived from host-virus conflict and regulate CRISPR-Cassystems. A WYL domain protein (s117009) has been shown to be a negativeregulator of the I-D CRISPR-Cas system in Synechocystis sp. (Hein etal., RNA Biol. (2013) 10: 852-864. In some instances, the WYL-containingprotein contains at least two WYL domains. These duplications areconsistent with the hypothesized multimeric assembly of theseligand-binding domains (Schumacher et al., EMBO J. (2002) 21:1210-4218).The N-termini of these WYL domains contain homology to transcriptionalrepressor CopG and the ParD anti-toxin domain. For use in eukaryotes,the WYL domain-containing proteins can be modified with a N- orC-terminal nuclear localization signal sequence (NLS). SEQ ID NOS:61-68present exemplary WYL domain-containing proteins modified with a sevenamino acid C-terminal NLS tag derived from the SV40 Large T-antigen.

TABLE 2 WYL domain sequences in various CasM-containing speciesSpecies/Isolate SEQ ID NO Eubacterium siraeum SEQ ID NO: 52 Ruminococcussp., isolate 2789STDY5834971 SEQ ID NO: 53 Ruminococcus bicirculans SEQID NO: 54 Ruminococcus sp., isolate 2789STDY5608892 SEQ ID NO: 55Ruminococcus sp. CAG:57 SEQ ID NO: 56 Ruminococcus flavefaciens FD-1 SEQID NO: 57 Ruminococcus albus strain KH2T6 SEQ ID NO: 58 Ruminococcusflavefaciens strain XPD3002 SEQ ID NO: 59

RtcB (RNA 3′-terminal phosphate cyclase, group B) is a protein domainsuperfamily and a RtcB homolog (SEQ ID NO. 60) proximal to the CasM locihas been identified. It has previously been reported that the CARFdomain has sequence similarity with the N-terminal domain of the RtcRprotein, which acts as the regulator of the Rtc RNA repair system. TheRtc system is comprised of the 3′-terminal phosphate cyclase RtcA andthe RNA ligase RtcB. The RtcB domain-containing proteins can be modifiedwith a N- or C-terminal NLS for use in eukaryotes. A RtcB domain with anassociated NLS derived from the SV40 Large T-antigen is shown in SEQ IDNO:69.

A modified CasM protein can have a low degree of sequence identity, amoderate degree of sequence identity, or a high degree of sequenceidentity over its length to a reference CasM protein, depending on theintended function of the CasM in question. By a “high degree of sequenceidentity” is meant approximately 90% sequence identity to 100% sequenceidentity, for example, about 90% . . . 95% . . . 98% sequence identityor higher. A “moderate degree of sequence identity” is typically betweenabout 80% sequence identity to about 85% sequence identity, for example,about 80% identity or higher, such as about 85% sequence identity. A“low degree of sequence identity” is typically between about 50%identity and 75% identity, for example, about 50% identity, preferablyabout 60% identity to about 75% identity.

In some embodiments, the amino acid sequence of the reference CasMprotein may be modified by deletion, insertion, or substitution of oneor more amino acid residues (either conservative or non-conservative innature), such that the activity of the CasM protein is either largelyretained, enhanced, or reduced. These modifications may be deliberate,as through site-directed mutagenesis, or may be accidental, such asthrough mutations of hosts that produce the proteins or errors due toPCR amplification.

Conservative substitutions are generally those substitutions that takeplace within a family of amino acids that are related in their sidechains. Specifically, amino acids are generally divided into fourfamilies: (1) acidic—aspartate and glutamate; (2) basic—lysine,arginine, histidine; (3) non-polar—alanine, valine, leucine, isoleucine,proline, phenylalanine, methionine, tryptophan; and (4) unchargedpolar—glycine, asparagine, glutamine, cysteine, serine threonine,tyrosine. Phenylalanine, tryptophan, and tyrosine axe sometimesclassified as aromatic amino acids. It is reasonably predictable that anisolated replacement of Leucine with isoleucine or valine, an aspartatewith a glutamate, a threonine with a serine, or a similar conservativereplacement of an amino acid with a structurally related amino acid,will not have a major effect on the desired biological activity. Forexample, the CasM protein may include up to about 5-10 conservative ornon-conservative amino acid substitutions, or even up to about 15-100 ormore, e.g., 50 or more, conservative or non-conservative amino acidsubstitutions, or any number between 5-100, so long as the desiredfunction of the molecule remains intact.

In other embodiments, it may be desirable to modify one or morecatalytic domains in order to render a nuclease-deactivated CasMprotein, also termed “catalytically inactive,” “catalytically deadCasM,” “dead CasM,” or “dCasM,” such that the protein either fails toproduce nucleic acid breaks, and/or binds a target sequence but does notcleave it. Such molecules lack all or a portion of nuclease activity andare unable to cleave a nucleic acid of interest and can therefore beused to regulate genes in a nucleic acid-guided manner. These deasMproteins can be used alone or in fusions to synthetically repress(CRISPRi) or activate (CRISPRa) gene expression.

The CasN1 proteins can either be directly isolated and purified frombacteria, or synthetically or recombinantly produced usingpolynucleotides encoding the same.

CasM Polynucleotides

Nucleic aid sequences encoding representative CasM proteins are shown inSEQ NOS:28-36 (see. Table 3) and these polynucleotides can be used toproduce CasM proteins as described herein.

TABLE 3 Representative CasM DNA Sequences Species/Isolate SEQ ID NOEubacterium siraeum SEQ ID NO: 28 Ruminococcus sp., isolate2789STDY5834971 SEQ ID NO: 29 Ruminococcus bicirculans SEQ ID NO: 30Ruminococcus sp., isolate 2789STDY5608892 SEQ ID NO: 31 Ruminococcus sp.CAG:57 SEQ ID NO: 32 Ruminococcus flavefaciens FD-1 SEQ ID NO: 33Ruminococcus albus strain KH2T6 SEQ ID NO: 34 Ruminococcus flavefaciensstrain XPD3002 SEQ ID NO: 35 Ruminococcus sp., isolate 2789STDY5834894SEQ ID NO: 36

These polynucleotides can be designed to encode native CasM proteins,such as the proteins depicted in SEQ ID NOS:37-45 (see Table 1);homologs thereof, including orthologs found in other species; or othervariants thereof. Moreover, a casM polynocleotide sequence can bemodified to have a low degree of sequence identity, a moderate degree ofsequence identity, or a high degree of sequence identity, over itslength to a reference casM polynucleotide, depending on the intendedfunction of the encoded CasM in question. By “a high degree of sequenceidentity” is meant approximatel,y 90% sequence identity to 100% sequenceidentity, for example, about 90% . . . 95% . . . 98% sequence identityor higher. A “moderate degree of sequence identity” is typically betweenabout 80% sequence identity to about 85% sequence identity, for example,about 80% identity or higher, such as about 85% sequence identity. A“low degree of sequence identity” is typically between about 50%identity and 75% identity, for example, about 50% identity, preferablyabout 60% identity to about 75% identity.

In some embodiments, the polynucleetide sequences are modified toenhance expression in a selected host cell. Codon usage bias refers todifferences in the frequency of occurrence of synonymous codons incoding DNA. For example, for the 20 standard amino acids in the geneticcode, there are 64 different codons (61 codons encoding for amino acids,and 3 stop codons). The overabundance in the number of codons allowsseveral amino acids to be encoded by more than one codon. The geneticcodes of different organisms are often biased towards the usage of oneof the several codons that encode a particular amino acid. Thus, agreater frequency of one codon will be found than expected by chance inparticular organisms. Accordingly, in order to enhance expression in aparticular host cell, it is often desirable to manipulatepolynueleotides to include codons that are biased for expression in theselected host cell. Several software packages are available online forthis, purpose. For example, a database from Integrated DNA Technologies,Coralville, Iowa (idtdna.com/CodonOpt), is a tool for producing modifiedsequences for expression in dozens of organisms. GeneScript, Piscataway,N.J., also provides modification tools through the OptimumGene™algorithm (genscript.com/codonopt.html?src=google&gclid=CIX3uoqexdICFRSUfgodu3sA1Q). See also, U.S.Pat. No. 8,326,547, incorporated herein by reference in its entirety.

Typically, polynucleotide sequences modified for expression inparticular host cells will display from about 50%-99% sequence identityto the native sequences, such as 60%-95%, e.g. 65% . . . 70% . . . 75% .. . 80% . . . 85% . . . 90% . . . 95% or more sequence identity, or anyinteger between these ranges, to the native sequences.

Using these tools, polymicleotide sequences can be modified forexpression in any commonly used host cell, such as but not limited to,bacterial cells and eukaryotic cells, including without limitation,bacterial cells such as E. coli, Lactoccoeus Pseudomonas systems,Streptomyces systems, Bacillus subtilis systems, Brevibacillus systems,coryneform bacteria, and halophilic bacteria; algal cells; yeast andother fungal cells; plant cells; mammalian cells such as human cells;insect cells, and the like.

SEQ ID NOS:1-9 show representative CasM-encoding polynucleotidesequences modified for expression in E. coli cells (see Table 4). SEQ IDNOS:10-18 show representative CasM-encoding polynucleotide sequencesmodified for expression in human cells (see Table 5). SEQ ID NOS:19-27show CasM-encoding polynucleotide sequences modified for expression inZea mays cells (see Table 6).

TABLE 4 Representative casM DNA Sequences Modified for Expression in E.coli Species/Isolate SEQ ID NO Eubacterium siraeum SEQ ID NO: 1Ruminococcus sp., isolate 2789STDY5834971 SEQ ID NO: 2 Ruminococcusbicirculans SEQ ID NO: 3 Ruminococcus sp., isolate 2789STDY5608892 SEQID NO: 4 Ruminococcus sp. CAG:57 SEQ ID NO: 5 Ruminococcus flavefaciensFD-1 SEQ ID NO: 6 Ruminococcus albus strain KH2T6 SEQ ID NO: 7Ruminococcus flavefaciens strain XPD3002 SEQ ID NO: 8 Ruminococcus sp.,isolate 2789STDY5834894 SEQ ID NO: 9

TABLE 5 Representative casM DNA Sequences Modified for Expression inHuman Cells Species/Isolate SEQ ID NO Eubacterium siraeum SEQ ID NO: 10Ruminococcus sp., isolate 2789STDY5834971 SEQ ID NO: 11 Ruminococcusbicirculans SEQ ID NO: 12 Ruminococcus sp., isolate 2789STDY5608892 SEQID NO: 13 Ruminococcus sp. CAG:57 SEQ ID NO: 14 Ruminococcusflavefaciens FD-1 SEQ ID NO: 15 Ruminucuccus albus strain KH2T6 SEQ IDNO: 16 Ruminococcus flavefaciens strain XPD3002 SEQ ID NO: 17Ruminococcus sp., isolate 2789STDY5834894 SEQ ID NO: 18

TABLE 6 Representative casM DNA Sequences Modified for Expression in Zeamays Species/Isolate SEQ ID NO Eubacterium siraeum SEQ ID NO: 19Ruminococcus sp., isolate 2789STDY5834971 SEQ ID NO: 20 Ruminococcusbicirculans SEQ ID NO: 21 Ruminococcus sp., isolate 2789STDY5608892 SEQID NO: 22 Ruminococcus sp. CAG:57 SEQ ID NO: 23 Ruminococcusflavefaciens FD-1 SEQ ID NO: 24 Ruminococcus albus strain KH2T6 SEQ IDNO: 25 Ruminococcus flavefaciens strain XPD3002 SEQ ID NO: 26Ruminococcus sp., isolate 2789STDY5834894 SEQ ID NO: 27

The casM polynucleotides can also be modified to include sequencesencoding N- or C-terminal nuclear to localization signal sequences(NiS), such as for expression in eukaryotic cells. Such sequences areknown, and include, without limitation, an NLS tag derived from the SV40 Large T-antigen. Such as tag is present at the C-terminus of theproteins shown in SEQ ID NOS:61-69 (i.e., the last seven amino acids inthese sequences).

The casM polynucleotides can be used Lo recombinantly produce CasMproteins using methods well known in the art.

CasM Complexes

CasM proteins can be complexed to a cognate nucleic acid guide (cognateguide/CasM complex) in order to deliver CasM in proximity with a targetnucleic acid sequence. A cognate guide, such as a crRNA, is apolynucleotide that site-specifically guides a CasM nuclease, or adeactivated CasM nuclease, to a target nucleic acid region. The bindingspecificity is determined jointly by the complementary region on thecognate guide and a short DNA motif (protospacer adjacent motif or PAM)juxtaposed to the complementary region. The spacer present in the guidespecifically hybridizes to a target nucleic acid sequence and determinesthe location of a Cas protein's site-specific binding and nucleolyticcleavage.

Cognate guide/CasM complexes can be produced using methods well known inthe art. For example, the guide components of the complexes can beproduced in vitro and CasM components can be recombinantly produced andthen the guides and CasM proteins can be complexed together usingmethods known in the art. Additionally, cell lines constitutivelyexpressing CasM proteins can be developed and can be transfected withthe guide components, and complexes can be purified from the cells usingstandard purification techniques, such as but not limited to affinity,ion exchange and size exclusion chromatography. See, e.g., Jinek M., etal., “A programmable dual-RNA-guided DNA endonuclease in adaptivebacterial immunity,” Science (2012) 337:816-821.

Alternatively, the components, is the cognate guides and casMpolynucleotides may be provided separately to a cell, e.g., usingseparate constructs, or together, in a single construct, or in anycombination, and complexes can be purified as above.

Methods of designing particular guides, such as for use in thecomplexes, are known. See, e.g., Briner et al., “Guide RNA FunctionalModules Direct Cas9 Activity and Orthogonality,” Molecular Cell (2014)56:333-339. To do so, the genomic sequence for the gene to be targetedis first identified. The exact region of the selected gene to targetwill depend on the specific application. For example, in order toactivate or repress a target gene using, for example, Cas activators orrepressors, cognate guide/CasM complexes can be targeted to the promoterdriving expression of the gene of interest. For genetic knockouts,guides are commonly designed to target 5′ constitutively expressed exonswhich reduces the chances or removal of the targeted region from mRNAdue to alternative splicing. Exons near the N-terminus can be targetedbecause frameshift mutations here will increase the likelihood of theproduction of a nonfunctional protein product. Alternatively, cognateguides can be designed to target exons that code for known essentialprotein domains. In this regard, non-frameshift mutations such asinsertions or deletions are more likely to alter protein function whenthey occur in protein domains that are essential for protein function.For gene editing using HDR, the target sequence should be close to thelocation of the desired edit. In this case, the location where the editis desired is identified and a target sequence is selected nearby.

The guides can be delivered to a cell. If the cell constitutivelyexpresses a CasM nuclease, the CasM nuclease will then be recruited tothe target site to cleave the target nucleic acid. If the cell does notexpress a CasM nuclease, complexes of cognate guide/CasM can bedelivered to the cells to make breaks in the genome, thereby triggeringthe repair pathways in the cells.

Treated cells are then screened using methods well known in the art,such as using high-throughput screening techniques including, but notlimited to, fluorescence-activated cell sorting (FACS)-based screeningplatforms, microfluidics-based screening platforms, and the like. Thesetechniques are well known in the art. See, e.g., Wojcik, et al., Int. J.Molec. Sci. (2015) 16:24918-24945. The cells can then be expanded andre-transfected with additional cognate guide/CasM complexes to introducefurther diversity and this process can be repeated iteratively until apopulation with the desired properties is obtained. Single cell clonesare sorted from the population, expanded and sequenced to recover themutations that resulted in the desired function.

Applications of CasM

Due to its RNA-targeting abilities, CasM can be used to edit RNA and insome embodiments, to treat diseases caused by toxic RNA or improperlyspliced RNA.

In some embodiments cognate guide/CasM complexes, such as, but notlimited to crRNA/Cash complexes, are capable of sequence-specific ssRNAactivity. Recognition and cleavage of an initial ssRNA complementary tothe crRNA target sequence activates the CasM protein to carry outendonuclease activity toward any single-stranded RNA in asequence-independent manner. The sequence-specific recognition of RNA ofthe crRNA/CasM complex facilitates the target knockdown of genetranscripts perturbing translation of a specific protein. Thenon-specific endonuclease activity of an activated crRNA/CasM complex ina cellular environment can result in cell death due to depletion of RNAencoding for essential gene transcripts. Thus, the specific RNAtargeting and collateral endonuclease activity of an activatedcrRNA/CasM complex enables the sequence-specific selection of cellsexpressing a RNA transcript.

Thus, in further aspects, CasM complexes, such as, but not limited tocrRNA/CasM complexes, can be used in methods of screening and killingcells, such as bacterial cells, that have not been modified by a DNAtargeting nuclease (i.e., a Type II Cas9 nuclease). This methodcomprises contacting a NATNA/Cas9 complex to a locus of interest in apopulation of cells. Contacting the NATNA/Cas9 complex with the locusresults in DNA cleavage and subsequent repair of the break by theendogenous cellular repair machine and the introduction of indels at thebreak site. The targeting of the NATNA/Cas9 complex to a targeted locusthat encodes an RNA transcript results in indels in an RNA transcriptsequence. This modified RNA transcript sequence is different compared toa transcript from an unmodified cell (a wild-type cell). A crRNA/CasMcomplex can then be targeted to the unmodified transcript, whereincrRNA/CasM recognition of the unmodified transcript results inactivation of the sequence independent, single-stranded RNA targetingactivity of the CasM protein and subsequent cell death. Alternatively,this method can be adapted to screen for the incorporation of adonor-polynucleotide into NATNA/Cas9 break site.

In another aspect, CasM complexes can by targeted to a eukaryotic exoncoding region to cause exon skipping. This method comprises contacting acrRNA/deactivated CasM complex, such as, but not limited to acrRNA/dCasM complex, with either a donor site (5′ end of an intron), abranch site (proximal to the 3′ end of an intron), or an acceptor site(5′ of an exon) of a pre-mRNA. Contacting the crRNA/dCasM complex to thevarious regions involved in exon splice events prevents the propersplicing of one of more exons together and causes the target exon to be“skipped”, and thus is not included in the mature mRNA and thereforeomitted from the translated polypeptide sequence.

In yet another aspect, CasM complexes are used for the detection of oneor more target molecules in vitro. This method comprises contacting acognate guide/CasN4 complex, such as a crRNA complex, with a ssRNAtarget of interest within a pool of nucleic acids. The crRNA/CasMcomplex can be added to a sample potential containing the ssRNA targetof interest, in combination with a quenched fluorescent RNA reportersfor example a RNA hexamer with a 6-Carboxyfluorescein at the 5′ end anda Iowa Black® FQ quencher (Integrated DNA Technologies, Coralville,Iowa) at the 3′ end. Contacting of the crRNA/CasM complex with the ssRNAtarget, activates the CasM protein to carry out collateral cleavage ofthe quenched fluorescent RNA reporter where cleavage of the reporter andresulting in an increase fluorescence that can by read out using aspectrophotometer. The gain in fluorescence is used as a measure of thepresents of a ssRNA target of interest.

In another aspect, CasM can be used for the targeted cleavage of anendogenous mRNA transcript while simultaneously delivering an exogenousmRNA transcript in cells. This method comprises contacting a cognateguide/CasM complex, with a disease-associated endogenous mRNAtranscript, while simultaneously delivering of a mRNA coding for thenon-disease exogenous polypeptide into a cell. Thus, thedisease-associated phenotype is repressed while the non-diseasephenotype is restored.

The CasM proteins described herein can also be used with associatedcognate guides in order to activate or repress a target gene, toknockout a gene, to produce a nonfunctional protein product, or to alterprotein function. The present invention includes methods of modulatingin vitro or in vivo transcription using the various components andcomplexes described herein. In one embodiment, a cognate guide/CasMprotein complex can repress gene expression by interfering withtranscription when the cognate guide directs nucleic acid target bindingof the complex to the promoter region of the gene. Use of the complexesto reduce transcription also includes complexes wherein the CasM proteinis fused to a known down-regulator of a target gene (e.g., a repressorpolypeptide). For example, expression of a gene is under the control ofregulatory sequences to which a repressor polypeptide can bind. Acognate guide can direct nucleic acid target-binding of a repressorprotein complex to the sequences encoding the regulatory sequences oradjacent the regulatory sequences such that binding of the repressorprotein complex brings the repressor protein into operable contact withthe regulatory sequences. Similarly, CasM can be fused to an activatorpolypeptide to activate or increase expression of a gene under thecontrol of regulatory sequences to which an activator polypeptide canbind.

In one embodiment, CasM can be fused with a nuclease, or a mutant or anactive portion thereof, as well as a cognate guide, in order to bringthe nuclease into proximity with a target nucleic acid sequence, whereinthe nuclease can produce a single-strand or double-strand break. In thisway, a locus-specific cut in a target nucleic acid can be achieved usinga cognate guide in combination with CasM, and the nuclease of interest.For example, it may be desirable to associate CasM with a restrictionendonuclease in order to cleave at a particular restriction site in atarget nucleic acid sequence. The restriction endonuclease can beselected from any of the various types of restriction endonucleases,such as, but not limited to, type I, II, III or IV. See, e.g., PCTPublication No. WO 2013/098244 to Brouns et al., published 4 Jul. 2013,incorporated herein by reference in its entirety, for methods ofproducing complexes between a Cas protein and a restrictionendonuclease.

Using the methods described herein, any desired nucleic acid sequence,and in particular RNA sequences, for modification can be targeted,including without limitation, protein coding mRNA sequences, in order toreduce or restore the function of the gene product; regions that have apropensity to incorporate nucleotide sequences from a donor template,termed “HDR hotspots” herein; safe harbor regions, i.e., regions wherenucleotide sequences can be inserted without disrupting neighboring genefunction; non-coding regulatory regions in nucleic acid sequences; andthe like.

Protein coding sequences, including RNA such as mRNA, for targeting bythe methods described herein include, but are not limited to, mammalianantibodies (ABs) (IgG, IgA, IgM, IgE), antibody fragments such as Fcregions, antibody Fab regions, antibody heavy chains, antibody lightchains, antibody CDRs, nanobodies, chimeric antibodies and other IgGdomains; T cell receptors (TCR); endonucleases and exonucleases, such asTALENS, CRISPR nucleases such as Cas9, Cas3, Cpfl, ZnFN, mega nucleases,nuclease domains such as HNH domain, RuvC domain; recombinases such asCre, Tre, Brec1, Flp, γ-integrase, IntI4 integrase, XerD recombinase,HP1 integrase; DNA topoisomerases; transposons such as the Tc1/marinerfamily, Tol2, piggyBac, Sleeping beauty; RAG proteins; retrotransposonssuch as LTR-retrotransposons and non-LTR retrotransposons (Alu, SINE,LINE); enzymes including but, not limited to arginases, glycosydases,proteases, kinases, and glycosylation enzymes such asglycosyltransferase; anticoagulants such as protein C, Protein S andantithrombin; coagulants such as thrombin; nucleases such as DNAses,RNAses, helicases, GTPases; DNA or RNA binding proteins; reportermolecules, such as Green Fluorescent Protein (GFP); cell penetratingpeptides and their fusions with cargo proteins; membrane proteins suchas GPCRs, pain receptors such as TRP channels and ion channels; cellsurface receptors including but not limited to EGFR, FGFR, VEGFR, IGFRand ephrin receptor; cell adhesion molecules like integrins andcadherins; ion channels; rhodopsins; immunoreceptors such as CD28, CD80,PD-1, PD-L1, CTLA-4, CXCR4, CXCR5, B2M, TRACA, TRBC; proteins known tobe involved with genetic defects; secreted proteins including but notlimited to hormones, cytokines, growth factors; vaccine antigens such asviral proteins from human immunodeficiency virus (HIV), Dengue,cytomegalovirus (CMV), Ebola, Zika and oncolytic viruses; snake toxinproteins and peptides including but not limited to phospholipases andmetalloproteases; ribosomal cyclic peptides.

The present invention also encompasses genome engineering methods forpreventing or treating diseases, disorders, and conditions using thevarious methods described herein. In one embodiment, a genomeengineering method uses the introduction of nucleic acid sequences intoan organism or cells of an organism (e.g., patient) to achieveexpression of components of the present invention to providemodification of a target function. For example, cells from an organismmay be engineered, ex vivo, by (i) introduction of vectors comprisingexpression cassettes expressing the various components, (ii) directintroduction of a NATNA and/or donor polynucleotides and CasM proteins,or (iii) introduction of combinations of these components. Theengineered cells are provided to an organism (e.g., patient) to betreated.

Examples of genome engineering and techniques for therapy are known inthe art (see, e.g., Kay, M. A., Nature Reviews Genetics (2011)12:316-328; Wang et al., Discov. Med. (2014) 18:67-77; Wang et al.,Discov. Med. (2014) 18:151-61; “The Clinibook: Clinical Gene TransferState of the Art,” Odile Cohen-Haguenauer (Editor), EDP Sciences (Oct.31, 2012), ISBN-10: 2842541715).

In some aspects, components of the present invention are delivered usingnanoscale delivery systems, such as nanoparticles. Additionally,liposomes and other particulate delivery systems can be used. Forexample, vectors including the components of the present methods can bepackaged in liposomes prior to delivery to the subject or to cellsderived therefrom, such as described in U.S. Pat. Nos. 5,580,859;5,264,618; 5,703,055, each of which is incorporated herein by referencein its entirety. Lipid encapsulation is generally accomplished usingliposomes that are able to stably bind or entrap and retain nucleicacid.

The methods described herein can also be used to generate non-humangenetically modified organisms, such as mice, plants, and the like.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. From the abovedescription and the following Examples, one skilled in the art canascertain essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make changes,substitutions, variations, and modifications of the invention to adaptit to various usages and conditions. Such changes, substitutions,variations, and modifications are also intended to fall within the scopeof the present disclosure.

EXPERIMENTAL

Aspects of the present invention are further illustrated in thefollowing Examples. Efforts have been made to ensure accuracy withrespect to numbers used (e.g., amounts, concentrations, percent changes,etc.) but some experimental errors and deviations should be accountedfor. Unless indicated otherwise, temperature is in degrees Centigradeand pressure is at or near atmospheric. It should be understood thatthese Examples, while indicating some embodiments of the invention, aregiven by way of illustration only.

The following Examples are not intended to limit the scope of what theinventors regard as various aspects of the present invention.

Example 1 Discovery of a New CRISPR-Associated (Cas) Protein In Silico

This Example describes the in silico discovery of a new Cas protein,termed “CasM,” from genomic sequencing data. The overall approach usedwas similar to methods described in Shmakov et al., “Discovery andfunctional characterization of diverse Class 2 CRISPR-Cas systems”Molecular Cell (2015) 60:385-397. In particular a computational pipelinewas used to search sequencing claw for CRISPR arrays in whole genomesand metagenic contigs.

Every contig or genome in the data set was inspected to determine if itcontained a CRISPR array using Minced (github.com/ctSkennertor/minced)and PILERCR (drive5.com/pilercr/).

Any time a CRISPR array was found in a contig or genome, the surroundingDNA sequence (up to 10 kilobases on either side of the CRISPR array) wasfurther inspected for open reading frames (ORFs) using the tool getorf(emboss.sourceforge.net/apps/cvs/emboss/apps/getorf.html).

The primary amino acid sequence of each predicted ORF was analyzed forpotential functional domain annotations using the tool HHPred (homologydetection & structure prediction by HMM-HMM comparison;toolkit.tuebingen.mpg.de/hhpred). HHPred allows the user to specifywhich databases to compare the amino acid sequence against to findsimilar protein domains. The databases searched included PFAM (whichincludes a large collection of protein families; http://pfam.xfam.org/),PDB (protein databank; wwpdb.org), CDD (conserved domain database;ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml), and KEGG (Kyoto Encyclopediaof Genes and Genomes; genome.jp/kegg/).

Using these tools, ORFs encoding a new putative CRISPR-associatedprotein, termed “CasM,” was found in several species in the Clostridiafamily. The ORFs are proximal to a predicted HTH DNA binding proteinwith homology to, a CRISPR-associated WYL domain. See

FIG. 1 for a representative map of a CRISPR operon found in Eubacteriumsiraeum (Genome Accession No. NZ_DS499551.1, coordinates211.800-220.497). The various CRISPR locus features are described inTable 7.

TABLE 7 CasM CRISPR locus for Eubacterium siraeum (FIG. 1) 101corresponds to the CasM open reading frame (ORF) (Protein accession:WP_005358205.1) 102 corresponds to a CRISPR Array 103 corresponds to anORF containing a RctB RNA ligase domain (Protein accession:WP_005358214.1) 104 corresponds to an ORF containing a WYL DNA bindingdomain (Protein accession: WP_005358216.1)

The results of HHPred analysis were analyzed to determine if theCasM-encoding ORFs had predicted domains commonly found inCRISPR-associated proteins. No annotations were found for CasM, thusindicating that the protein was novel.

The sequences for the various native CasM proteins are shown in SEQ IDNOS:37-45 (see Table 1) and the native polynucleotides encoding thereforare shown in SEQ ID NOS:28-36 (see Table 3). This protein has nosignificant homology to any known protein families or to any Class 2 Caseffectors.

Example 2 Codon Modification of Native casM Sequences

This Example describes the process of codon optimizing CasM codingsequences to improve expression in selected host cells.

Native casM nucleotide sequences were retrieved from the referencegenomes or metagenomic contigs of the host microbes as described inExample 1. The amino acid sequences of the coding regions were generatedwith the ExPASy DNA translation tool (web.expasy.org/translate/). Next,these amino acid sequences were entered into the Integrated DNATechnologies (Coralville, Iowa) Codon Optimisation tool(idtdna.com/CodonOpt). “Amino acid” was chosen for the “Sequence Type”option and “Gene” was chosen for the “Product Type” option. For eachnative casM sequence, codon modifications were performed to increaseexpression in E. coli, human, and Zea mays cells.

SEQ ID NOS:1-9 show the modified sequences for use in E. coli (see Table4). SEQ ID NOS:10-19 show the modified sequences for use in human cells(see Table 5). SEQ ID NOS:20-27 show the modified sequences for use inZ. mays cells (see Table 6). Table 8 shows the percent identity of themodified sequences to the native sequences.

TABLE 8 Percent Sequence Identity to Native casM Sequences modifiedmodified modified for for for casM bacterial strain E. coli cells humancells Z. mays cells Eubacterium siraeum 75% 77% 77% Ruminococcus sp.,isolate 77% 76% 76% 2789STDY5834971 Ruminococcus bicirculans 76% 76% 77%Ruminococcus sp., isolate 76% 75% 77% 2789STDY5608892 Ruminococcus sp.CAG:57 76% 77% 76% Ruminococcus flavefaciens 76% 77% 76% FD-1Ruminococcus albus strain 76% 77% 77% KH2T6 Ruminococcus flavefaciens76% 77% 77% strain XPD3002 Ruminococcus sp., isolate 75% 76% 78%2789STDY5834894

Example 3 Production of CasM Expression Plasmids for DNA InterferenceAssays

This Example describes the production of plasmids that express the CasMprotein.

The modified casM nucleotide sequences set forth in Example 2 weresynthesized in vitro. The DNA sequences were cloned into an appropriateplasmid for expression in E. coli.

For E. coli expression, the E. coli-modified sequences were cloned intoa p14A plasmid backbone using appropriate restriction nucleases. Theplasmid backbone contained a T7 promoter upstream of the CasM codingsequence to facilitate transcription in cells.

The p14A plasmid backbone also contained a cloning site enabling theinsertion of a minimal CRISPR array. The minimal CRISPR array containedone repeat sequence, followed by one spacer sequence, followed by onerepeat sequence. The plasmid backbone also contained a T7 promoterupstream of the CRISPR array site, a kanamycin resistance gene, and aColE1 origin of replication.

Similar techniques are used for preparing plasmids for expression inhuman and Zea mays cells. Once the plasmids are produced, they aretransfected into the selected cell, e.g., E. coli, human, or plant cells(e.g., Zea mays cells).

Example 4 Plasmid Interference Assay

This Example describes the use of CasM in an assay to evaluate itsability to cleave double-stranded DNA in the form of a target plasmid.The overall approach is similar to methods used in Burnstein et al.,Nature (2016) 542:237-241.

The CasM expression plasmid in Example 3 is transformed into E. colicells. The cells are grown in a medium containing kanamycin to selectonly for cells that contain the CasM expression plasmid.

A target plasmid is constructed that contains the spacer sequencecontained in the CRISPR array of the CasM expression plasmid. Adjacentto the spacer sequence is a randomized PAM sequence of 7 nucleotides.Plasmid libraries containing randomized PAM sequences are assembled byannealing a DNA oligonueleotide containing a target with a 7 ntrandomized PAM region with a primer and extended with Klenow Fragment(New England Biolabs, Ipswitch, Mass.). The double-stranded DNA isdigested with EcoRI and NcoI and ligated into a pUC19 backbone. Theligated library is transformed into E. coli DH5α and cells areharvested, the plasmids extracted and purified. 200 ng of the pooledlibrary is transformed into electro-competent E. coli harboring a CRISPRlocus or a control plasmid with no locus. The transformed cells areplated on selective media containing carbenieillin (100 mg L⁻¹) andchloramphenicol (30 mg L⁻¹) for 30 hours at 25° C. Plasmid DNA isextracted and the PAM sequence is amplified with adapters for liluminasequencing. The 7 nt PAM region is extracted and PAM frequenciescalculated for each 7 nt sequence. PAM sequences depleted above thespecified threshold are used to generate a sequence logo with WebLogo(weblogo.berkeley.edu). If depleted PAMs are present, this shows thatthe nuclease is a double-stranded DNA nuclease,

Example 5 Targeted Modification of HEK293 Cells Using CasM

This Example illustrates the use of CasM to modify human embryonickidney (HEK293) cells at specific target locations.

casM polynucieotides are transfected into HEK293 cells constitutivelyexpressing a CasM-GFP fusion (HEK293-CasM-GFP), using the Nucleofector™96-well Shuttle System (Lonza, Allendale, N.J.) and the followingprotocol. The casM polynucleotides are designed to target the FUT8 gene.Equal molar amounts of cask/ polynucleotide components are prepared inan annealing buffer (1.25 in HEPES, 0.625 mM MgCl₂, 9.375 mM KCl at pH7.5), incubated for 2 minutes at 95° C., removed from the thermocycler,allowed to equilibrate to room temperature, and dispensed in a 10 μLfinal volume in a 96-well plate. Culture medium is aspirated fromHEK293-CasM-GFP cells, and the cells are washed once with calcium andmagnesium-free PBS and then trypsinized by the addition of TrypLE (LifeTechnologies, Grand Island, N.Y.) followed by incubation at 37° C. for3-5 minutes. Trypsinized cells are gently pipetted up and down to form asingle cell suspension and added to DMEM complete culture mediumcomposed of DMEM culture medium (Life Technologies, Grand Island, N.Y.)containing 10% FBS (Fisher Scientific, Pittsburgh, Pa.) and supplementedwith penicillin and streptomycin (Life Technologies, Grand Island,N.Y.).

The cells are then pelletcd by centrifugation for 3 minutes at 200×g,the culture medium aspirated and cells resuspended in PBS. The cells arecounted using the Countess™ II Automated Cell Counter (LifeTechnologies, Grand Island, N.Y.). 2.2×10⁷ cells are transferred to a 50ml tube and pelleted. The PBS is aspirated and the cells resuspended inNucleofector™ SF (Lonza, Allendale, N.J.) solution to a density of1×10⁷cells/mL. 20 μL of the cell suspension are then added to individualwells containing 10 μL of casM polynucleotide components and the entirevolume is transferred to the wells of a 96-well Nucleocuvette™ Plate(Lonza, Allendale, N.J.). The plate is loaded onto the Nucleofector™96-well Shuttle™ (Lonza, Allendale, N.J.) and cells are nucleofectedusing the 96-CM-130 Nucleofector™ program (Lonza, Allendale, N.J.).Post-nucleofection, 70 μL DMEM complete culture medium is added to eachwell and 50 μL of the cell suspension are transferred to a collagencoated 96-well cell culture plate containing 150 μL pre-warmed DMEMcomplete culture medium. The plate is then transferred to a tissueculture incubator and maintained at 37° C. in 5% CO₂ for 48 hours.

Genomic DNA (gDNA) is prepped using the QuickExtract DNA extractionsolution (IIlumina, San Diego, Calif.) pursuant to the manufacturerinstructions. Sequencing amplicons of between 150 bp to 200 bp aredesigned to span the CasM RNP FUT8 target site. Using previouslyisolated gDNA, a first PCR is performed using Herculase II Fusion DNAPolyinerase™ (Agnew, Santa Clara, Calif.) with primers comprising anadapter sequences and a sequence specific to the region flanking thePUT8 target site. A second PCR is performed using the amplicons of thefirst round of PCR as template at 1/20^(th) the volume of the PCRreaction volume. The second PCR uses a second set of primers comprisinga sequence complementary to the adapter sequence of the first primerpair, a barcode index sequence unique to each sample, and a flow celladapter sequence. Amplicons are pooled and analyzed on a 2% TBE gel andbands of expected amplicon sizes are gel purified using the QIAES II Gelextraction kit™ (Qiagen, Venlo, Luxembourg). The concentrations ofpurified amplicons are evaluated using the double-stranded DNA BR. AssayKit and Qubit system™ (Life Technologies, South San Francisco, Calif.)and library quality determined using the Agilent DNA100Chip and AgilentBioanalyzer 2100 system™ (Agilent, Santa Clara, Calif.). Aftervalidation of library quality, the library is sequenced on a MiSeqBenchtop Sequencer™ (Illumina, San Diego, Calif.) with the MiSeq ReagentKit v2™ (300 cycles, Illumina, San Diego, Calif.) per manufacturerinstructions for 151 bp paired end reads.

The identity of products in the sequencing data is analyzed based uponthe index barcode sequence adapted onto the amplicon in the second roundof PCR. A computational script is used to process the MiSeq data byexecuting the following tasks:

-   -   1. Joining paired end reads with the aid of fastq-join (Amnesty        2011: code.google.com/p/ea-utils);    -   2. Validating the sequence reads for appropriate primer        sequences being present at both 5′ and 3′ ends of the read        sequence using fastx_barcode_splitter        (hannonlab.cshl.edu/fastx_toolkit/index.html); reads lacking        correct primer sequences at both ends are discarded.    -   3. Comparing Read sequences to expected wild type FUT8 sequence;        identical read sequences are classified as having the same ladel        modification.

Other chromosomal loci within HEK293 cells are similarly modified byselection of an appropriate spacer sequence for the CasM RNP. Selectionis specific to a specific gene target and the procedure outlined in thisExample is readily modifiable by one of ordinary skill in the art forother gene targets.

This procedure can provide data to verify the CasM RNP and to detectnucleic acid guided nuclease activity at targeted loci in HEK293 cells.

Example 6 CasM CRISPR Array Processing Assay

Example describes the CRISPR array processing activity of a CasMprotein. The following method may be practiced with other CasM proteinhomologs to characterize their CRISPR array processing capabilities.

A. Identification of the CRISPR Array Repeat Sequence

The CRISPR array of the CasM protein homolog (SEQ ID NO:39) was analyzedin silico and the repeat sequence identified. The in silico structure ofa CRISPR repeat sequence (SEQ ID NO:51) associated with the CasM protein(SEQ ID NO:39) as predicted using an RNA folding algorithm(rna.urmc.rochester.edu/RNA structureWeb/Servers/Predict1.html) is shownin FIG. 2 (SEQ ID NO:51). The various CRISPR repeat sequence structuralcomponents represented in FIG. 2 are described in Table 9.

TABLE 9 Numerical Indicators Used to Illustrate CasM CRISPR RepeatSequence Structural Components (FIG. 2) 470 corresponds to a 5′ repeathandle sequence 471 corresponds to a stem-duplex formed by a first stemduplex stand hybridized to a second stem duplex strand 472 correspondsto a loop sequences 473 corresponds to a 5′ repeat handle sequence 474corresponds to the 3′ attachment point of a spacer sequence 475corresponds to the CRISPR repeat processing positions performed by CasMupon guide binding 10 indicates the tenth nucleotide position 20indicates the twentieth nucleotide position 30 indicates the thirtiethnucleotide position

The repeat sequence was used to design a CRISPR array by incorporatingspacer sequences 5′, 3′, or both 5′ and 3′ of the repeat sequence. Thesequences were used for synthesis as RNA. The synthetic CasM CRISPRarray is represented in FIG. 4 and structural components 470-473 aredetailed in Table 9. Additional components 490 and 491 correspond to afirst 5′ and a first 3′ spacer sequence, respectively. The CRISPR arraycomponents are shown in Table 10.

TABLE 10 CRISPR Array Components CRISPR SEQ ID Array Size NO:Configuration Sequence (nt) SEQ ID spacer-repeat-UGAUACUGCUUUGAUGUCAGCAUUGC 96 NO: 46 spacer AUAUCUACUAUACUGGUGCGAAUUUGCACUAGUCUAAAAUCUAUAACCAUAA GUUCUUCUGCGUUCAUAU SEQ ID spacer-repeatUGAUACUGCUUUGAUGUCAGCAUUGC NO: 47 AUAUCUACUAUACUGGUGCGAAUUUG 66CACUAGUCUAAAAU SEQ ID repeat-spacer CUACUAUACUGGUGCGAAUUUGCACU NO: 48AGUCUAAAAUUGAUACUGCUUUGAUG 66 UCAGCAUUGCAUAU *CRISPR repeat sequence isunderlined

SEQ ID NO:46 comprises, in a 5′ to 3′ orientation, CRISPR arraystructural components 490, 470-473, and 491. SEQ ID NO:47 comprises, ina 5′ to 3′ orientation, CRISPR array structural components 490 and470-473. SEQ ID NO:48 comprises, in a 5′ to 3′ orientation, CRISPR arraystructural components 470-473 and 491.

Alternative to synthesis, CRISPR arrays may be made via PCR using 3′overlapping primers containing DNA sequences corresponding to CRISPRarray components and incorporation of a T7 promoter sequence 5′ of theCRISPR arrays, followed by in vitro transcription.

B. CasM Purification

The CasM protein coding sequence was codon-optimized for expression inE. coli and incorporated into a modified pET plasmid backbone downstreamof a maltose binding protein (MBP) using appropriate restrictionnucleases. The plasmid backbone contained a T7-Lac promoter upstream ofthe MBP-CasM coding sequence to facilitate transcription in cells.Additionally, the plasmid backbone contained an kanamycin resistancegene and a ColE1 origin of replication.

The CasM expression plasmid was transformed into Rosetta2 (DE3) cells,and cells were grown in two 1L shake flasks at 37° C. until cellsreached an optical density of 0.6, after which protein expression wasinduced by addition of 0.5 mM IPTG. Cells were then incubated at 16° C.overnight.

Cells were collected via centrifugation and lysed via sonication. Celldebris was pelleted, and the clarified lysate was purified using acombination of HisTrap column chromatography, followed by cleavage ofthe MBP tag, and finally cation exchange column chzomatography. Finalpurified protein was quantified using a NanoDrop™ 2000 spectrophotometer(ThermoFisher, Waltham, Mass.), and stored at −80° C.,

C. In Vitro CRISPR Array Processing

Synthetic CRISPR array reagents were resuspended in water to a finalconcentration of 250 μM and diluted to a working concentration of 250nM. CRISPR arrays were incubated at 95° C. for two minutes and cooled by0.5° C./sec in a thermocycler to a final temperature of 25° C.

CasM was diluted to a final concentration of 500 nM in 1× cleavagebuffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl₂, and 5% glycerol at pH 7.4).The reaction was initiated by addition of CasM protein to denaturedCRISPR arrays in a final reaction volume of 12 μL, followed byincubation at 37° C. for 15 minutes. The reaction was terminated by heatinactivation at 95° C. for 2 minutes, and 6 of the reaction was mixedwith 6 μL of 2×RNA loading buffer (New England Biolabs, Ipswich, Mass.).Low Range ssRNA Ladder™ (New England Biolabs, Ipswich, Mass.) wasdiluted 125-fold in water and 7 μL were mixed with 7 μL of 2×RNA LoadingDye™ (New England Biolabs, Ipswich, Mass.) and incubated at 90° C. for 4minutes and then incubated on ice for 5 minutes. CRISPR array processingreactions and ssRNA ladder were analyzed on a Mini-PROTEAN 15% TEE-Urea™(Bio-RAD, Hercules, Calif.) run at 200 V for 1 hour in 1×TBE runningbuffer. The gel was stained using 2×SYBR gold™ (MilliporeSigma, St.Louis, Mich.) for 15 minutes and visualized using a Gel DocTM EZ system™(Bio-RAD, Hercules, Calif.). The results of the CRISPR array processingreactions are shown in FIG. 3 and lane order is presented in Table 11.

TABLE 11 CRISPR Array Cleavage Gel Lane Order CRISPR Array LaneConfiguration SEQ ID NO: CasM 1 Low Range ssRNA Ladder 2spacer-repeat-spacer SEQ ID NO: 46 − 3 spacer-repeat SEQ ID NO: 47 − 4repeat-spacer SEQ ID NO: 48 − 5 spacer-repeat-spacer SEQ ID NO: 46 + 6spacer-repeat SEQ ID NO: 47 + 7 repeat-spacer SEQ ID NO: 48 +

The results of the CRISPR array cleavage assays (FIG. 3) demonstratedthat the CasM protein is capable of processing a cognate CRISPR array.The three bands shown in Lane 1 correspond to 150, 80 and 50 nucleotidestandards of the Low Range ssRNA Ladder™ (New England Biolabs, Ipswich,Mass.), respectively). Indicator 480 in FIG. 3 corresponds to aprocessed CasM crRNA comprising a portion of the CRISPR repeat sequenceand a spacer sequence. Indicator 481 corresponds to RNA species cleavedfrom the 5′ end of the CRISPR array following addition of CasM.

The CasM cleaved nucleotides in the 5′ region of the repeat element(FIG. 3, comparing Lane 2 to 5; comparing Lane 3 to Lane 6), andexhibited no cleavage 3′ of the repeat element (FIG. 3, comparing Lane 4to Lane 7). crRNA proceeded from the CasM CRISPR array and therefore hada 5′ repeat element and a spacer element 3′ of the repeat. In theabsence of CasM, no cleavage of the crRNA was observed (FIG. 3, Lanes 2,3, and 4).

Schematics of the crRNA processing regimes are depicted in FIG. 5. InFIG. 5, panel I corresponds to the reaction in FIG. 3, Lane 5; FIG. 5panel II corresponds to the reaction in FIG. 3, Lane 6; and FIG. 5 panelIII corresponds to the reaction in FIG. 3, Lane 7. The variouscomponents represented in FIG. 5 are described in Table 12.

TABLE 12 Numerical Indicators Used to Illustrate the Results of the invitro CRISPR Array Cleavage Assay (FIG. 5) 492 corresponds to aspacer-repeat-spacer CRISPR array (SEQ ID. NO: 46) 493 corresponds to aspacer-repeat CRISPR array (SEQ ID. NO: 47) 494 corresponds to arepeat-spacer CRISPR array (SEQ ID. NO: 48) 495 corresponds to a CasMprotein 496 corresponds to a processed crRNA 497 corresponds to a RNAspecies cleaved from the 5′ end of the CRISPR array 498 corresponds to aprocessed CRISPR repeat sequence 499 corresponds to a RNA speciescleaved from the 5′ end of the CRISPR repeat sequence

Example 7 CasM ssRNA Cleavage Assay

This Example illustrates the use of a crRNA/CasM protein complex tocarry out ssRNA cleavage. The following method may be practiced withother CasM protein and crRNA to cleave ssRNA targets.

A. Generation of ssRNA Target

A ssRNA target was generated via PCR amplification of a 224 nucleotidetarget sequence from a plasmid. A T7 promoter sequence was incorporatedinto the 5′ end of the reverse PCR primer (SEQ ID NO:50) fortranscription. The primers used for ssRNA target DNA template arepresented in Table 13.

TABLE 13 ssRNA Target DNA Template Primers SEQ ID NO: Name SequenceSEQ ID NO: 49 Forward CGAAATTAATACGACTCACTATAGG primerTTTCGATTATGCGGCCGTGT SEQ ID NO: 50 Reverse AGGAGATATACCATGGGCAGCAprimer * T7 Promoter sequence underlined.

The primers were present at a concentration of 400 nM each. PCRreactions were performed using Q5 Hot Start High-Fidelity 2× Master Mix™(New England Biolabs, Ipswich, Mass.) following the manufacturer'sinstructions with 10 ng of plasmid template. PCR assembly reactions werecarried out using the following thermal cycling conditions: 98° C. for 2minutes; 20 cycles of 10 seconds at 98° C.; 15 seconds at 60° C.; 30seconds at 72° C.; and a final extension at 72° C. for 2 minutes. DNAproduct quality was evaluated after the PCR reaction by agarose gelelectrophoresis (1.5%, SYBR® Safe; Life Technologies, Grand Island,N.Y.).

Between 0.1-0.5 μg of the amplified ssRNA target DNA template was usedas a template for transcription using T7 High Yield RNA Synthesis Kit™(New England Biolabs, Ipswich, Mass.) for approximately 16 hours at 37°C. Transcription reactions were treated with DNase 1 (New EnglandBiolabs, Ipswich, Mass.) and purified using GeneJet RNA Cleanup andConcentration Kit™ (Life Technologies, Grand Island, N.Y.). The qualityof the transcribed RNA was checked by agarose gel electrophoresis (2%,SYBR® Safe; Life Technologies, Grand Island, N.Y.) and quantified usingthe Quant-iT™ RNA Assay Kit™ (ThermoFisher, Waltham, Mass.).

B. Designing CasM crRNA

The 224 nucleotide ssRNA target sequence was probed in silico for a 30nucleotide target sequence. The target sequence was appended in silicoto the 3′ end of the CasM crRNA repeat sequence and the crRNA sequencewas provided to a commercial manufacturer for synthesis.

C. ssRNA Cleavage Assay

Synthetic crRNA reagents were resuspended in water to a finalconcentration of 250 μM and diluted to a suitable working concentrationof 250 nM. In vitro transcribed ssRNA target was diluted to 43 ng/μL inwater. Both the crRNA and the ssRNA target reagents were separatelyincubated, at 95° C. for two minutes and cooled by 0.5° C./sec in athermocycler to a final temperature of 25° C. The CasM protein wasdiluted to various concentrations in water and 1× cleavage buffer.Denatured crRNA was added at various concentrations to the CasM proteinand incubated in a thermocycler for 10 minutes at 37° C. The cleavagereactions were initiated by the addition of the ssRNA target to a finalconcentration of 56.4 nM in a final, reaction volume of 12 μL. Theconcentration of each component in the various reactions is shown inTable 14.

TABLE 14 ssRNA Targeting Reaction Component Concentrations Molar rationM nM ssRNA CasM:crRNA:ssRNA Reaction nM CasM crRNA target target 1 11.333.8 56.4 0.2:0.6:1 2 22.5 67.6 56.4 0.4:1.2:1 3 33.8 101.5 56.40.6:1.8:1 4 45.1 135.3 56.4 0.8:2.4:1 5 56.4 169.1 56.4 1:3:1 6 112.7338.2 56.4 2:6:1 7 225.5 676.4 56.4 4:12:1 8 338.2 1014.6 56.4 6:18:1 9450.9 1352.8 56.4 8:24:1 10 563.7 1691.0 56.4 10:30:1 11 0.0 0.0 56.40:3:1 12 56.4 0.0 56.4 1:0:1 13 0.0 169.1 56.4 0:3:1 14 0.0 169.1 0.01:3:0

Samples were mixed and centrifuged briefly before being incubated for 1hour at 37° C. Reactions were terminated by incubating the reaction at95° C. for 2 minutes followed by the addition of 100 U/μL of ProteinaseK (New England Biolabs, Ipswich, Mass.), 4 M urea, 5 μM DTT, 50 μM EDTAand incubation at 37° C. for 15 minutes. 7 μL of each reaction was mixedwith 6 μL of 2×RNA Loading Dye (New England Biolabs, Ipswich, Mass.) andincubated at 90° C. for two minutes. Low Range ssRNA Ladder™ (NewEngland Biolabs, Ipswich, Mass.) was diluted 125-fold in water and 7 μLwere mixed with 7 μL of 2×RNA Loading Dye™ (New England Biolabs,Ipswich, Mass.) and incubated at 90° C. for 4 minutes and then incubatedon ice for 5 minutes. Cleavage reactions and ssRNA ladder were analyzedon a Mini-PROTEAN 15% TBE-Urea™ (BioRAD, Hercules, Calif.), run at 200 Vfor 1 hour in 1×TBE running buffer. Gel was stained using 2×SYBR gold™(Life Technologies, Grand Island, N.Y.) for 15 minutes and visualizedwith using a Gel Doc EZ system™ (BioRAD, Hercules, Calif.). The resultsof the crRNA cleavage assay are shown in FIG. 6 and the components ofeach lane shown in Table 15. Numerical indicator 500 corresponds to thessRNA target. Numerical indicator 501 corresponds to a ssRNA targethybridized to the spacer sequences of the CasM crRNA. Numericalindicator 502 corresponds to an unprocessed CasM crRNA. Numericalindicator 503 corresponds to the processed CasM crRNA species.

TABLE 15 ssRNA Cleavage Gel Lane Order Molar ratio CasM:crRNA:ssRNA Lanetarget 1 0.2:0.6:1 2 0.4:1.2:1 3 0.6:1.8:1 4 0.8:2.4:1 5 1:3:1 6 2:6:1 74:12:1 8 6:18:1 9 8:24:1 10 10:30:1 11 ssRNA Ladder 12 0:3:1 13 1:0:1 140:3:1 15 1:3:0

The results of the ssRNA cleavage assay shown in FIG. 6 demonstratedthat a CasM:crRNA protein complex was capable of ssRNA target cleavage.The results of this procedure demonstrate that increasing the amount ofCasM:crRNA complexes resulted in decreased amounts of ssRNA target (FIG.6, indicator 500) visualized on the gel (FIG. 6, Lanes 1-10).

Example 8 Production of CasM and RtcB Expression Plasmids for MS2 PhageDrop Plaque Assays

This Example describes the production of plasmids for the expression ofCasM, RtcB (RNA 3°-terminal phosphate cyclase, group B), and acorresponding CRISPR array in E. coli for use in a MS2 phage drop plaqueassay. The following method can be practiced with other CasM, RtcB, andCRISPR array homologs.

The casM and rtcB nucleotide sequence from Eubacterium siraeum (SEQ IDNO:37 and SEQ ID NO:60, respectively) are selected and codon optimizedfor expression in E. coli. The E. coli-modified sequences are clonedinto a p14A plasmid backbone using appropriate restriction nucleases.The plasmid backbone contains a T7 promoter upstream of each proteincoding sequence to facilitate transcription in cells. Two controlplasmids, one containing only the casM gene sequence under the controlof a T7 promoter and the other plasmid only containing the rtcB genesequence under the control of a T7 promoter, can also constructed.

A spacer sequence that has homology with the MS2 phase genome isengineered in silico flanked 5′ and 3′ by the Eubacterium siraeum CasMCRISPR repeat sequence. A non-targeting spacer with no homology to theMS2 phage or E. coli genome, is similarly engineered as a control. Bothsequences are subcloned into separate plasmids between an upsteam T7promoter sequence and a downstream transcription terminator sequence.

Example 9 MS2 Phage Drop Plaque Assay

This Example describes the use of CasM and RtcB in an assay to evaluatethe ability of the RtcB protein to modulate CasM's sequence-specific andcollateral nuclease activity in E. coli. The method set forth herein isadapted from Smargon et al., Molec. Cell (2017) 65:618-630. Not all ofthe following steps are required for screening, nor must the order ofthe steps be as presented.

The expression plasmids constructed in Example 8 are in and incombination transformed into BL21(AI) E. coli cells from a commercialprovider, such as Invitrogen (Carlsbad, Calif.). Transformed cells aregrown overnight at 37° C., with shaking, in lysogeny broth (LB)supplemented with 100 μg/mL carbenicillin, to select for cells thatcontain the CasM expression plasmid.

The following day, cells are diluted 1:100 and then grown at 37° C.,with shaking, to an OD600 of 2.0. The cells are then mixed with 4 mL ofcarbenicillin-containing top Agar (10 g/L tryptone, 5 g/L yeast extract,10 g/L sodium chloride, 5 g/L agar) and poured onto LB-antibiotic baseplates. The top agar also contains 0.2% arabinose to induce expressionof the casM, ricB and CRISPR array coding sequences. 10-fold serialdilutions of MS2 phage (ATCC 15597-B1, Manassas Va.) are made in LB andthen spotted onto hardened top agar with a multi-channel pipette. Plaqueformation is assessed after overnight incubation of the spotted platesat 37° C.

To assess whether the RtcB protein modulates CasM cleavage activity, therelative plaque formation is determined by comparing cells expressingCasM, RtcB, and the CRISPR array targeting MS2 phage; cells expressingCasM and the CRISPR array targeting MS2 phage, and cells expressing CasMand the CRISPR array not targeting MS2 phage; cells expressing CasM andRtcB only.

Example 10 Introduction of CasM RNP Complexes into Target Cells

This Example illustrates the design and delivery of CasM and crRNAribonucleoprotein (RNP) complexes into human cells to enable mRNAcleavage of the human epidermal growth factor receptor (EGFR) gene andsubsequent knockdown of EGFR gene expression.

A. Production of CasM Complexes and Transformation into Cells

Mature crRNAs (SEQ ID NOS:70-165) were designed to target the EGFR locusin the human genome. Each crRNA contained a 5′ 36 nt repeat (SEQ IDNO:51) followed by a 30 at spacer. crRNAs were designed to target 72unique sequences complementary to the egfr mRNA within exons 1-3.Sequences were designed such that flanking sequences within 1 bp werenot biased by any nucleotide. As negative controls, not predicted toinduce cleavage, crRNAs were also designed to target (1) eight genomicsequences upstream of the predicted egfr mRNA; (2) eight sequencescomplementary to the vegfa mRNA exon 1; and (3) eight sequencesidentical to the egfr mRNA.

Double-stranded DNA (dsDNA) guide templates containing upstream T7promoter sequences were created by annealing complementaryoligonucleotides (Integrated DNA Technologies, Coralville, Iowa) at afinal concentration of 10 μM in annealing buffer (30 mM HEPES, 300 mMKCL), then incubating at 95° C. for, two minutes, and then slowly cooledto approximately 25° C., and incubated for an additional 20 minutes.Following annealing, guides were transcribed with T7 RNA polymeraseHiScribe™ T7 High Yield RNA Synthesis Kit™ (New England Biolabs,Ipswich, Mass.) according to manufacturer's instructions. Next, sampleswere digested with RNase-free DNase-I (New England Biolabs, Ipswich,Mass.) according to manufacturer's instructions, then purified usingRNAClean XP™ beads (Beckman Coulter, Indianapolis, Ind.).

For RNAClean XP™ bead purification, 30 μL of sample was combined with155 μL of 100% isopropanol and 10 μL of 3 M sodium acetate and thenmixed thoroughly. Next, 50 μL of RNAClean XP™ beads were incubated on amagnet for three minutes to allow separation of the liquid and beads,and the supernatant was removed. Subsequently, the samples containingcrRNA were added to the beads, mixed, incubated at approximately 25° C.for five minutes, then incubated on a magnet for three minutes. Finally,the supernatant was removed, the beads were washed once with 83%ethanol, dried, and then the crRNA was eluted in 20 μL of molecularbiology grade water. crRNAs were quantified using ribogreen and thennormalized to 1 μg/μL.

To assemble CasM RNPs, 120 pmols of each unique crRNA were added to awell then incubated at 95° C. for two minutes followed by 5° C. forapproximately 10 minutes. Next, the denatured crRNA guides were combinedwith 20 pmol of CasM (SEQ ID NO:39) in RNP assembly buffer (20 mM HEPES;pH 7.4, 10 nuM MgCl₂, 150 mM KCl, 5% glycerol) and then incubated at 37°C. for 10 minutes.

B. Transfection of CasM RNP Complexes into Eukaryotic Cells

HeLa cells (ATCC, Manassas, Va.) were cultured in suspension in DMEMmedium supplemented with 10% FBS and 1× Antibiotic-Antimycotic Solution(Mediatech, Inc., Manassas, Va.) at 37° C., 5% CO2 and 100% humidity.HeLa cells were transfected using the Nueleofector® 96-well ShuffleSystem (Lonza, Allendale, N.J.). Prior to nucleofection, 5 μl of theCasM:crRNA RNPs were assembled in individual wells of a 96-well plate.HeLa cells were transferred to a 50 ml conical centrifuge tube andcentrifuged at 200×G for live minutes. The media was aspirated and thecell pellet was washed in calcium and magnesium-free PBS. The cells werecentrifuged once more and resuspended in Nucleofector SF™ buffer (Lonza,Allendale, N.J.) at a concentration of 5×10⁶ cells/ml. 20 μl of thiscell suspension was added to the CasM:crRNA RNPs in the 96 well plate,mixed, and then the entire volume was transferred to a 96-wellNucleocuvette™ Plate. The plate was then loaded into the Nucleofector96-well Shuttle™ and cells were nucleofected using the 96-CN-114Nucleofector™ program (Lonza, Allendale, N.J.). Immediately followingnucleofection, 75 μl of complete DMEM medium was added to each well ofthe 96-well Nucleocuvette™ Plate. Half of the contents of each well werethen transferred to a 96-well tissue culture plate containing 150 μl ofcomplete DMEM medium. This procedure was then repeated in order to platea duplicate for each well, one which would be used for lysis and genomicDNA analysis, and one for FACS analysis. The cells were cultured at 37°C., 5% CO2 and 100% humidity for approximately 5 days.

C. FACS Analysis of CasM Mediated EGFR Knockdown

Fluorescence activated cell sorting (FACS) analysis was performed 5 daysafter nucleofection of HeLa cells with EGFR-targeting CasM2 RNPs. Inbrief: 2×10⁵-4×10⁵ cells/well were detached with TrypLE Express (Gibco),stained with 2 μL APC anti-human EGFR (Clone AY13, Sony Biotechnology)in 100 μL, total volume and then analyzed using Intellicyte FlowCytometer (Intellicyt, Albuquerque, N.M.). Results from theseexperiments are shown in Table 16.

TABLE 16 CasM Mediated EGFR knockdown % EGFR negative crRNA SEQ ID Namecells transcription NO. Untransfected reference cell 2% n/a — Intergenictarget-1 5% Intergenic SEQ ID NO: 70 Intergenic target-2 6% IntergenicSEQ ID NO: 71 Intergenic target-3 9% Intergenic SEQ ID NO: 72 Intergenictarget-4 8% Intergenic SEQ ID NO: 73 Intergenic target-5 5% IntergenicSEQ ID NO: 74 Intergenic target-6 6% Intergenic SEQ ID NO: 75 Intergenictarget-7 6% Intergenic SEQ ID NO: 76 Intergenic target-8 4% IntergenicSEQ ID NO: 77 Exon 1 target-1 6% Exon 1/28 SEQ ID NO: 78 Exon 1 target-25% Exon 1/28 SEQ ID NO: 79 Exon 1 target-3 5% Exon 1/28 SEQ ID NO: 80Exon 1 target-4 4% Exon 1/28 SEQ ID NO: 81 Exon 1 target-5 6% Exon 1/28SEQ ID NO: 82 Exon 1 target-6 5% Exon 1/28 SEQ ID NO: 83 Exon 1 target-76% Exon 1/28 SEQ ID NO: 84 Exon 1 target-8 6% Exon 1/28 SEQ ID NO: 85Exon 1 target-9 4% Exon 1/28 SEQ ID NO: 86 Exon 1 target-10 3% Exon 1/28SEQ ID NO: 87 Exon 1 target-11 3% Exon 1/28 SEQ ID NO: 88 Exon 1target-12 2% Exon 1/28 SEQ ID NO: 89 Exon 1 target-13 4% Exon 1/28 SEQID NO: 90 Exon 1 target-14 4% Exon 1/28 SEQ ID NO: 91 Exon 1 target-155% Exon 1/28 SEQ ID NO: 92 Exon 1 target-16 4% Exon 1/28 SEQ ID NO: 93Exon 1 target-17 6% Exon 1/28 SEQ ID NO: 94 Exon 1 target-18 6% Exon1/28 SEQ ID NO: 95 Exon 1 target-19 6% Exon 1/28 SEQ ID NO: 96 Exon 1target-20 5% Exon 1/28 SEQ ID NO: 97 Exon 1 target-21 5% Exon 1/28 SEQID NO: 98 Exon 1 target-22 5% Exon 1/28 SEQ ID NO: 99 Exon 1 target-236% Exon 1/28 SEQ ID NO: 100 Exon 1 target-24 5% Exon 1/28 SEQ ID NO: 101Exon 2 target-1 6% Exon 2/28 SEQ ID NO: 102 Exon 2 target-2 7% Exon 2/28SEQ ID NO: 103 Exon 2 target-3 11%  Exon 2/28 SEQ ID NO: 104 Exon 2target-4 5% Exon 2/28 SEQ ID NO: 105 Exon 2 target-5 6% Exon 2/28 SEQ IDNO: 106 Exon 2 target-6 8% Exon 2/28 SEQ ID NO: 107 Exon 2 target-7 11% Exon 2/28 SEQ ID NO: 108 Exon 2 target-8 10%  Exon 2/28 SEQ ID NO: 109Exon 2 target-9 13%  Exon 2/28 SEQ ID NO: 110 Exon 2 target-10 8% Exon2/28 SEQ ID NO: 111 Exon 2 target-11 10%  Exon 2/28 SEQ ID NO: 112 Exon2 target-12 8% Exon 2/28 SEQ ID NO: 113 Exon 2 target-13 13%  Exon 2/28SEQ ID NO: 114 Exon 2 target-14 16%  Exon 2/28 SEQ ID NO: 115 Exon 2target-15 19%  Exon 2/28 SEQ ID NO: 116 Exon2 target-16 11%  Exon 2/28SEQ ID NO: 117 Exon 2 target-17 10%  Exon 2/28 SEQ ID NO: 118 Exon 2target-18 19%  Exon 2/28 SEQ ID NO: 119 Exon 2 target-19 20%  Exon 2/28SEQ ID NO: 120 Exon 2 target-20 25%  Exon 2/28 SEQ ID NO: 121 Exon 2target-21 15%  Exon 2/28 SEQ ID NO: 122 Exon 2 target-22 17%  Exon 2/28SEQ ID NO: 123 Exon 2 target-23 14%  Exon 2/28 SEQ ID NO: 124 Exon 2target-24 12%  Exon 2/28 SEQ ID NO: 125 Exon 3 target-1 7% Exon 3/28 SEQID NO: 126 Exon 3 target-2 7% Exon 3/28 SEQ ID NO: 127 Exon 3 target-39% Exon 3/28 SEQ ID NO: 128 Exon 3 target-4 9% Exon 3/28 SEQ ID NO: 129Exon 3 target-5 8% Exon 3/28 SEQ ID NO: 130 Exon 3 target-6 11%  Exon3/28 SEQ ID NO: 131 Exon 3 target-7 12%  Exon 3/28 SEQ ID NO: 132 Exon 3target-8 12%  Exon 3/28 SEQ ID NO: 133 Exon 3 target-9 10%  Exon 3/28SEQ ID NO: 134 Exon 3 target-10 9% Exon 3/28 SEQ ID NO: 135 Exon 3target-11 11%  Exon 3/28 SEQ ID NO: 136 Exon 3 target-12 40%  Exon 3/28SEQ ID NO: 137 Exon 3 target-13 17%  Exon 3/28 SEQ ID NO: 138 Exon 3target-14 15%  Exon 3/28 SEQ ID NO: 139 Exon 3 target-15 12%  Exon 3/28SEQ ID NO: 140 Exon 3 target-16 21%  Exon 3/28 SEQ ID NO: 141 Exon 3target-17 48%  Exon 3/28 SEQ ID NO: 142 Exon 3 target-18 41%  Exon 3/28SEQ ID NO: 143 Exon 3 target-19 19%  Exon 3/28 SEQ ID NO: 144 Exon 3target-20 9% Exon 3/28 SEQ ID NO: 145 Exon 3 target-21 19%  Exon 3/28SEQ ID NO: 146 Exon 3 target-22 8% Exon 3/28 SEQ ID NO: 147 Exon 3target-23 8% Exon 3/28 SEQ ID NO: 148 Exon 3 target-24 6% Exon 3/28 SEQID NO: 149 VEGFA target-1 6% Exon 1/8 SEQ ID NO: 150 VEGFA target-2 8%Exon 1/8 SEQ ID NO: 151 VEGFA target-3 8% Exon 1/8 SEQ ID NO: 152 VEGFAtarget-4 7% Exon 1/8 SEQ ID NO: 153 VEGFA target-5 8% Exon 1/8 SEQ IDNO: 154 VEGFA target-6 7% Exon 1/8 SEQ ID NO: 155 VEGFA target-7 6% Exon1/8 SEQ ID NO: 156 VEGFA target-8 8% Exon 1/8 SEQ ID NO: 157Nontargeting target-1 5% Exon 1/28 SEQ ID NO: 158 Nontargeting target-27% Exon 1/28 SEQ ID NO: 159 Nontargeting target-3 6% Exon 1/28 SEQ IDNO: 160 Nontargeting target-4 6% Exon 1/28 SEQ ID NO: 161 Nontargetingtarget-5 6% Exon 1/28 SEQ ID NO: 162 Nontargeting target-6 6% Exon 1/28SEQ ID NO: 163 Nontargeting target-7 7% Exon 1/28 SEQ ID NO: 164Nontargeting target-8 4% Exon 1/28 SEQ ID NO: 165

The data presented in Table 16 shows that CasM did not produce egfrknockdown when targeted to (1) sequences upstream of the predicted exon1 start site using SEQ ID NOS:70-77; (2) an unrelated vascularendothelial growth factor A (vegfa) gene using SEQ ID NOS:150-157); or(3) the reverse complement of sequences contained in egfr exon 1 mRNAusing SEQ ID NOS:158-165. Conversely, CasM enabled approximately 40%egfr knockdown when targeted to mRNA sequences contained in exon 2 usingSEQ ID NO:102-125, and exon 3 of egfr using SEQ ID NO:126-149.

Although preferred embodiments of the subject methods have beendescribed in some detail, it is understood that obvious variations canbe made without departing from the spirit and the scope of the inventionas defined by the appended claims.

1. A Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR)-associated (Cas) nucleoprotein complex, wherein thenucleoprotein complex comprises a Cas protein having at least 95 percentsequence identity to the amino acid sequence of SEQ ID NO: 40; and acognate nucleic acid guide comprising a repeat sequence and a spacersequence, wherein the repeat sequetice and the spacer sequence do notnaturally occur together, wherein the Cas protein and the cognatenucleic acid guide form the nucleoprotein complex, and wherein thenucleoprotein complex is capable of site-directed binding to a targetnucleic acid sequence.
 2. The Cas nucleoprotein complex of claim 1,wherein the cognate nucleic acid guide comprises a crRNA.
 3. The Casnucleoprotein complex of claim 1, wherein the Cas protein comprises anN- or C-terminal nuclear localization signal sequence (NLS).
 4. The Casnucleoprotein complex of claim 1, wherein the cognate nucleic acid guidecomprises a modified base analog.
 5. The Cas nucleoprotein complex ofclaim 1, wherein the sequence identity is calculated using BLASTcomputer program with default parameters.
 6. A eukaryotic cellcomprising the Cas nucleoprotein complex of claim
 1. 7. The eukaryoticcell of claim 6, further comprising one or more additional Casnucleoprotein complexes.
 8. The eukaryotic cell of claim 7, wherein theeukaryotic cell is a human cell.
 9. The Cas nucleoprotein complex ofclaim 1, wherein the Cas protein is catalytically active.
 10. The Casnucleoprotein complex of claim 1, wherein the Cas protein iscatalytically inactive.
 11. The Cas nucleoprotein complex of claim 1,wherein the Cas protein comprises a fusion protein.
 12. An expressioncassette comprising: a polynucleotide encoding: a Clustered RegularlyInterspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein,wherein the Cas protein has at least 95 percent sequence identity to theamino acid sequence of SEQ ID NO: 40; and one or more cognate nucleicacid guides, wherein the one or more cognate nucleic acid guidescomprise a repeat sequence and a spacer sequence, wherein the repeatsequence and the spacer sequence do not naturally occur together,wherein the Cas protein is capable of forming one or more nucleoproteincomplexes with the one or more cognate nucleic acid guides, and whereineach nucleoprotein complex is capable of site-directed binding to atarget nucleic acid sequence.
 13. The expression cassette of claim 12,wherein the Cas protein is catalytically active.
 14. The expressioncassette of claim 12, wherein the Cas protein is catalytically inactive.15. The expression cassette of claim 12, further comprising one or morenucleic acid sequences each encoding a nuclear localization tag operablylinked to the polynucleotide encoding the Cas protein.
 16. A recombinantvector, comprising the expression cassette of claim
 12. 17. A eukaryoticcell, comprising the expression cassette of claim
 12. 18. Therecombinant vector of claim 16, wherein the vector is a viral vector.19. A method of directing a Clustered Regularly Interspaced ShortPalindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex to aselected nucleic acid target sequence, the method comprising: contactingthe selected nucleic acid target sequence with one or more nucleoproteincomplexes comprising: a Clustered Regularly Interspaced ShortPalindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Casprotein has at least 95 percent sequence identity to the amino acidsequence of SEQ ID NO: 40 and a cognate nucleic acid guide comprising arepeat sequence and a spacer sequence, wherein the repeat and the spacersequence do not naturally occur together, wherein the Cas protein andthe cognate nucleic acid guide form the nucleoprotein complex, andwherein the nucleoprotein complex binds to the selected nucleic acidtarget sequence.
 20. The method of claim 19, wherein the nucleic acidtarget sequence comprises RNA.
 21. The method of claim 19, wherein themethod is performed in a cell.
 22. The method of claim 19, wherein thenucleoprotein complex is capable of site-directed binding to the nucleicacid target sequence.